2026-04-15 (Query — cycle briefing)

• Action: query
• Question: "Brief me about cycles so far"
• Finding: Summarized all 4 documented Aza-Ven cycles from wiki. Cycle 1 (Dec 2025, Day 21 BMBx showed response), Cycle 2 (Jan 19, AZA 5d + VEN 10d, pegfilgrastim → bone pain), Cycle 3 (Mar 2, no G-CSF), Cycle 4+ (Apr 6–13, AZA 5d + VEN 5d, IV route). Treatment response positive: Hb 6.8→10.5, ANC 610→2590, Plt 45K→140K.
• Gaps noted: Cycle 1 and 3 exact AZA/VEN durations undocumented; drug doses unknown; LFTs missing; next response assessment timing unknown.
• Pages updated: none (informational summary of existing wiki content)

2026-04-15 (Patient note — Cycle 2 details: AZA 5 days, VEN 10 days)

• Action: ingest — patient clinical note via Telegram bot
• Source: raw/clinic-notes/2026-04-15_note_7.md
• Content: "second cycle was from Jan 19 5 days AZA and 10 days of VEN"
• Interpretation: Cycle 2 started 2026-01-19 (previously estimated ~2026-02-03). Azacitidine was given for 5 days and venetoclax for 10 days. Key findings:
• AZA 5-day schedule is not new — already in use by Cycle 2, not first introduced in Cycle 4+ as previously thought.
• VEN duration progressively reduced: 10 days (Cycle 2) → 5 days (Cycle 4+).
• Cycle 2 timing corrected: Jan 19 (confirmed) vs ~Feb 3 (previous estimate). Off by ~2 weeks. Inter-cycle spacing: Cycle 1 end (~Dec 16) → Cycle 2 start (Jan 19) = ~34 days.
• Pages updated: Aml (cycle table, schedule evolution note, source), Azacitidine (frequency, schedule history table, source), Venetoclax (frequency, schedule history table, source), Active Medications (schedule info), Overview (schedule evolution), Hot (cycle history, last ingest), Index (source count 42→43)
• Clinical significance: Progressive VEN reduction (10→5 days) while maintaining AZA at 5 days suggests active therapy de-escalation — a positive sign reflecting adequate treatment response.

2026-04-15 (Query — last cycle)

• Action: query
• Question: "Last cycle"
• Finding: Last cycle is Cycle 4+ (2026-04-06 to 2026-04-13). AZA 5 days IV + VEN 5 days. No pegfilgrastim. End-of-cycle labs: Hb 10.5, WBC 3500, Plt 140, ANC 2590. All from existing wiki content — no new information.
• Pages updated: none

2026-04-16 (Query — Hb trend)

• Action: query
• Question: "trend Hb"
• Finding: 23 data points from Sep 2022 – Apr 2026. Nadir 6.8 (2025-11-28) → peak 11.6 (2026-04-06). Latest 10.5 (2026-04-13). Overall positive trajectory with cyclical dips from myelosuppression. Still below normal (12.0). Pre-existing mild anemia (11.0 in 2022).
• Pages referenced: Hemoglobin, Hot
• Pages updated: none (existing trend analysis in hemoglobin.md is current)

2026-04-17 (Query — QoL bang for the buck)

• Action: query
• Question: "What's the most bang for the buck quality of life for her?"
• Finding: Top 5 highest-impact, lowest-effort QoL interventions identified: (1) Optimize Hb toward 12+ g/dL — single biggest fatigue driver, already trending up; (2) Workup hyponatremia — Na 133, causes cognitive fogging and fall risk, workup never done; (3) Cancer-related fatigue management — activity, nutrition, sleep; (4) Document allergy/transfusion reaction — allergy list still empty; (5) Obtain and verify LFTs — claimed normal but no source document.
• Pages referenced: Profile, Overview, Hot, Aml, Anemia, Hyponatremia, Pancytopenia, Diabetes Mellitus, Hemoglobin, Sodium, Allergy List
• Pages created: Qol Bang For Buck (synthesis)
• Pages updated: Index (syntheses section), Log

2026-04-17 (Refine — batch 1, 8 source files)

• Action: /refine pass
• Sources re-read: raw/assets/2026-04-15_photo_033816.jpg, raw/clinic-notes/2026-04-15_bijay-whatsapp-nov-dec-2025.md, raw/clinic-notes/2026-04-15_note_2.md through note_7.md
• Enrichments made:
• Profile — Added family/caretaker info: Sameer Badarudeen (son, remote coordinator), Nisha (bedside caretaker). Populated emergency_contact field.
• Aml — Corrected treating_provider from Ashwin V Nair to Bijay Prabhakaran Nair (Dr. Bijay makes all treatment decisions per WhatsApp evidence). Enriched Cycle 3 row with Dr. Bijay's full quote including "Best not to wait too long." Enriched transfusion reaction with Nisha's name and timestamps. Confirmed pegfilgrastim was given during Cycle 2 (not "likely during or after").
• Port Placement 2025 12 09 — Added Dr. Bijay's informed consent note (wanted to talk to patient before starting treatment).
• Karyotype 2025 11 29 — Added report details: 2-page document ("ishamma.pdf") shared via WhatsApp on 2025-12-08.
• Bone Marrow Biopsy 2025 11 28 — Added CBC Monday repeat plan detail.
• Pegfilgrastim — Confirmed Cycle 2 timing (changed from "likely during or after Cycle 2" to confirmed). Updated date_started from 2026-02-01 to 2026-01-19 (Cycle 2 start). Added Cycle 3 start date.
• Posaconazole — Corrected date_started from 2025-12-01 to 2025-12-09 (started when VEN started, i.e., Cycle 1).
• Bijay Prabhakaran Nair — Added informed consent note for Dec 9. Enriched Feb 25 entry with full quote, lab bill number (L01S608426), and "Best not to wait too long."
• Allergy List — Populated with transfusion reaction (2025-12-10): sudden chills and breathing difficulty. Added warning callout for future transfusion pre-medication.
• Overview — Added family/caretaker line.
• Hot — Added family info, updated transfusion reaction with Nisha reference and allergy-list link, added refinement log entry.
• Inaccuracies corrected:
• AML treating_provider: Ashwin V Nair → Bijay Prabhakaran Nair
• Pegfilgrastim date_started: 2026-02-01 → 2026-01-19
• Posaconazole date_started: 2025-12-01 → 2025-12-09
• Pegfilgrastim timing: "likely during or after Cycle 2" → confirmed Cycle 2
• No new pages created.

2026-04-17 (Refine — batch 2, 7 lab PDFs + 1 clinic note)

• Action: /refine pass
• Sources re-read: raw/clinic-notes/2026-04-15_note.md, raw/labs/4170ZB0011814170_849900t.pdf (2026-02-20 CBC+ESR), raw/labs/4182VI0091894182_910394a.pdf (2022-09-20 CBC+ESR+CRP+IgE+D-Dimer), raw/labs/4182VI0131054182_816476x.pdf (2022-09-27 CBC+ESR+CRP+IgE), raw/labs/4182YK0075724182_686599v.pdf (2025-11-19 comprehensive panel), raw/labs/4182YK0075744182_266603h.pdf (2025-11-19 peripheral smear), raw/labs/4182YK0075964182_221400g.pdf (2025-11-19 HbA1c), raw/labs/CCR_4182YK007572_296266q.pdf (2025-11-19 CCR with ANA/dsDNA/SPEP)
• New pages created (8):
• D Dimer — 1 data point: 0.48 ug/mL (2022-09-20, normal). No thrombosis during acute inflammatory episode.
• Total Ige — 2 data points: 203.1 and 134.4 IU/mL (Sep 2022, both elevated). Allergic/parasitic component to 2022 inflammatory episode.
• Ceruloplasmin — 1 data point: 29.10 mg/dL (2025-11-19, normal). Wilson's ruled out.
• Complement C3 — 1 data point: 140.0 mg/dL (2025-11-19, normal). No complement consumption.
• Complement C4 — 1 data point: 39.3 mg/dL (2025-11-19, normal upper end). No hypocomplementemia.
• Anti Ccp — 1 data point: <7.00 U/mL (2025-11-19, negative). RA ruled out.
• Peripheral Smear 2025 11 19 — Pre-AML peripheral smear: normocytic normochromic anemia (Hb 8.3), leucopenia with eosinophil predominance (13%), thrombocytopenia (60-80K), atypical lymphocytes (3%), no blasts, no haemoparasites.
• Lab Timeline — Populated chronological lab timeline with all 27 lab dates from Sep 2022 to Apr 2026.
• Existing pages enriched:
• Anc — Added 2025-11-19 data point (1090, neutropenic). Now 22 data points. Updated baseline analysis.
• Mcv — Added 2022-09-27 data point (87.5 fL, normocytic — pre-AML baseline) and 2026-02-20 (99.8 fL). Now 10 data points. Enriched trend analysis: shift from normocytic to macrocytic correlates with AML/MDS development.
• Rdw — Added 2026-02-20 data point (16.7%). Now 6 data points.
• Positive Ana — Added ceruloplasmin and copper to workup table. Added section for pending labs (SPEP, free light chains, copper — all reported PENDING on Nov 2025 reports). Added peripheral smear context (eosinophil predominance). Updated related_labs frontmatter.
• Lab Trends — Added "Additional Markers" section with 11 single/few-data-point markers. Added summary bullets for autoimmune workup and 2022 pre-AML baseline.
• Index — Added 8 new lab pages, updated page count to 52, updated ANC/MCV/RDW data point counts.
• Hot — Updated last refinement section, added SPEP and free light chains to pending/gaps.
• Key findings from deep read:
• The Nov 2025 comprehensive workup was more extensive than captured in pass 1: ceruloplasmin, C3, C4, Anti-CCP, peripheral smear, and several PENDING tests (SPEP, free light chains, copper) were missed.
• The 2022 inflammatory episode included D-Dimer (normal) and IgE (elevated) — adding allergic/parasitic context not previously documented.
• Peripheral smear showed eosinophil predominance (13%) and atypical lymphocytes — atypical for AML and raised alternative diagnoses before BMBx.
• MCV was normocytic (87.5 fL) in 2022, shifting to macrocytic by Nov 2025 — documenting the transition associated with AML/MDS.
• No inaccuracies corrected — all existing data was correct.

2026-04-17 (Refine — batch 3, 8 lab PDFs)

• Action: /refine pass
• Sources re-read: raw/labs/CCR_4182YK007572_734983f.pdf (FINAL DDRC report 2025-11-19), raw/labs/CCR_4182YK007572_784807r.pdf (preliminary version — same accession), raw/labs/File1000384802.pdf (2025-11-28 CBC KIMS), raw/labs/File2000384802.pdf (2025-11-28 flow cytometry), raw/labs/Ishamma 1.pdf (2026-02-17 CBC+electrolytes), raw/labs/ishamma.pdf (karyotype 46,XX), raw/labs/Ishamma T M 10.pdf (2026-01-16 CBC+electrolytes), raw/labs/Ishamma T M 11.pdf (2025-12-31 BMBx histopath)
• KEY FINDING: Final DDRC report (734983f.pdf) contains results previously marked PENDING on the preliminary report (784807r.pdf). Three lab results that were flagged as unresolved gaps are now available:
• SPEP — Inflammatory pattern, no M-spike. Total protein 7.42, A/G ratio 1.20.
• Serum free light chains — Kappa 36.81 (H), Lambda 26.73 (H), K/L ratio 1.377 (N). Polyclonal.
• Copper, serum — 124.5 ug/dL (normal).
• New pages created (3):
• Spep — SPEP with detailed fraction breakdown. Inflammatory pattern, no M-spike. Rules out myeloma/paraproteinemia.
• Free Light Chains — Kappa/Lambda free light chains. Polyclonal elevation with normal ratio. Monoclonal gammopathy ruled out.
• Copper Serum — Normal serum copper. Combined with normal ceruloplasmin, Wilson's disease ruled out.
• Pages enriched:
• Positive Ana — Copper result updated from PENDING to 124.5 (normal). SPEP/light chains/copper section updated from "unknown if finalized" to resolved with results. Added Copper Serum, Spep, Free Light Chains to related_labs.
• Ceruloplasmin — Removed "copper pending" warning. Added cross-reference to Copper Serum with result.
• Pancytopenia — Updated copper status from "pending" to resolved.
• Aml — Enriched SPEP section with detailed fraction data, added copper result, renamed section to "Myeloma Workup."
• Chloride — Added 2026-02-17 data point (97 mmol/L, L).
• Rbc Count — Added 2026-01-16 (2.96) and 2026-02-17 (3.41) data points.
• Mcv — Added 2026-01-16 (95.6) and 2026-02-17 (92.7) data points.
• Rdw — Added 2026-01-16 (19.1, highest recorded) and 2026-02-17 (17.3) data points.
• Lab Trends — Added copper, SPEP, free light chains rows. Added myeloma workup and copper metabolism summary bullets.
• Lab Timeline — Enriched 2025-11-19 entry with copper, SPEP, and free light chain results.
• Index — Added 3 new lab marker pages. Updated chloride data point count. Updated page count to 55.
• Hot — Marked copper, SPEP, and free light chains as RESOLVED. Added batch 3 refinement note.
• Verification notes:
• Files 1 & 2 (734983f and 784807r) are Final and Preliminary versions of the same DDRC accession (4182YK007572). Identical CBC/ESR/serology data; the Final adds copper result.
• File 3 (Nov 28 CBC) — all values already in wiki (Hb 6.8, WBC 2500, Plt 45, ANC 1240).
• File 4 (Nov 28 flow) — page exists with all details (FCM 147/25, 5% blasts, dilute sample).
• File 5 (Feb 17 CBC+electrolytes) — CBC already in wiki; electrolytes already in sodium (137) and chloride (now added: 97).
• File 6 (karyotype) — page exists with correct details (46,XX[10], sample received 2025-11-22, reported 2025-11-29).
• File 7 (Jan 16 CBC+electrolytes) — CBC already in wiki; electrolytes already in sodium (136).
• File 8 (Dec 31 BMBx histopath) — page exists with full details.

2026-04-17 (Refine — batch 4, 8 lab PDFs)

• Action: /refine pass
• Sources re-read: raw/labs/Ishamma T M 1 2.pdf (2026-03-25 CBC+Electrolytes KIMS), raw/labs/Ishamma T M 12.pdf (2025-11-17 PBF KIMS), raw/labs/Ishamma T M 1 3.pdf (2026-03-18 CBC+Electrolytes KIMS), raw/labs/Ishamma T M 13.pdf (2025-11-17 Folic Acid + Iron Profile KIMS), raw/labs/Ishamma T M 1 4.pdf (2026-03-12 CBC+Electrolytes KIMS), raw/labs/ISHAMMA T M 14.pdf (2025-07-05 Lipid+Metabolic Devi Scans), raw/labs/Ishamma T M 1 5.pdf (2026-02-04 CBC+Electrolytes KIMS), raw/labs/Ishamma T M 1 6.pdf (2026-01-28 CBC+Electrolytes KIMS)
• KEY FINDINGS:
• Peripheral Blood Film (2025-11-17) — A KIMS PBF predating the DDRC smear by 2 days. Shows pancytopenia with eosinophils 18% (even higher than DDRC's 13%). Macrocytes noted. Reported by Dr. Padmini R.
• Folic Acid & Iron Profile (2025-11-17) — Part of anemia workup by Dr. Mithun Padmanabhan. Folic acid >20 ng/ml (normal → folate deficiency ruled out). Transferrin 1.86 g/L (low), TSAT 16.5% (normal) → classic anemia of chronic disease pattern, not iron deficiency.
• Pre-AML Metabolic Baseline (2025-07-05, Devi Scans) — Comprehensive panel previously only partially captured (HbA1c, Na). Now fully extracted: Lipid panel (TC 165, TG 101, HDL 69, LDL 75 — optimal), Calcium 10.20 (normal), Creatinine 0.62 (normal), Urea 26 (normal), Potassium 4.13 (normal). Lab: Devi Scans Pvt. Ltd., approved by Dr. Soumya Jose.
• Electrolyte data enrichment — Potassium, bicarbonate, and chloride data points extracted from 5 KIMS CBC+Electrolyte reports (Jan 28, Feb 4, Mar 12, Mar 18, Mar 25) that previously only had CBC captured.
• New pages created (12):
• Peripheral Smear 2025 11 17 — KIMS PBF: pancytopenia, eosinophils 18%, macrocytes. Comparison table with Nov 19 DDRC smear.
• Folic Acid — >20 ng/ml, folate deficiency ruled out.
• Iron Profile — Transferrin 1.86 (L), TSAT 16.5% (N). Anemia of chronic disease.
• Lipid Panel — TC 165, TG 101, HDL 69, LDL 75, VLDL 20. Optimal.
• Calcium — 10.20 mg/dL, normal.
• Creatinine — 0.62 mg/dL, normal renal function.
• Urea — 26 mg/dL, normal.
• Potassium — 6 data points (Jul 2025 – Mar 2026), consistently normal.
• Bicarbonate — 5 data points (Jan – Mar 2026), consistently normal. Supports SIADH etiology for hyponatremia.
• Padmini R — Provider: Pathologist, KIMS Health.
• Soumya Jose — Provider: Consultant Pathologist, Devi Scans.
• Existing pages enriched:
• Rbc Count — Added 3 data points: Mar 18 (3.30), Mar 12 (3.25), Jan 28 (3.17). Now 15 data points.
• Mcv — Added 3 data points: Mar 18 (96.1), Mar 12 (92.0), Jan 28 (91.5). Now 14 data points.
• Rdw — Added 5 data points: Mar 25 (18.1), Mar 18 (18.6), Mar 12 (17.2), Feb 4 (18.2), Jan 28 (18.2). Now 13 data points.
• Chloride — Added 2 data points: Mar 18 (96), Jan 28 (94). Now 10 data points.
• Mithun Padmanabhan — Added folic acid and iron profile orders to his page.
• Lab Trends — Added 10 new markers to Additional Markers table. Added electrolyte panel, anemia workup, and pre-AML baseline summary bullets.
• Lab Timeline — Enriched Mar 25, Mar 18, Mar 12, Feb 4, Jan 28 entries with electrolyte data. Added Nov 17 (PBF + iron + folic acid) and Jul 5 (pre-AML metabolic panel) entries.
• Index — Added 12 new pages, updated data point counts, added 2 providers. Page count 55→67.
• Verification notes:
• Files Ishamma T M 1 2.pdf (Mar 25), Ishamma T M 1 3.pdf (Mar 18), Ishamma T M 1 4.pdf (Mar 12), Ishamma T M 1 5.pdf (Feb 4), Ishamma T M 1 6.pdf (Jan 28) — CBC data was already in wiki; electrolyte data was missing and has now been added.
• ISHAMMA T M 14.pdf (Jul 5 Devi Scans) — HbA1c and sodium were already in wiki; lipid panel, calcium, creatinine, urea, and potassium were missing.
• Ishamma T M 12.pdf (Nov 17 PBF) — entirely new to the wiki.
• Ishamma T M 13.pdf (Nov 17 Folic Acid + Iron Profile) — entirely new to the wiki.
• No inaccuracies corrected — all existing data was correct.

2026-04-17 (Refine — batch 5, 8 lab PDFs)

• Action: /refine pass
• Sources re-read: raw/labs/Ishamma T M 1 7.pdf (2026-01-19 CBC+LFT+Electrolytes+Ca/Cr KIMS), raw/labs/Ishamma T M 1.pdf (2026-04-13 CBC+Electrolytes KIMS), raw/labs/Ishamma T M 2.pdf (2026-03-30 CBC+Electrolytes KIMS), raw/labs/Ishamma T M 3.pdf (2026-03-05 CBC+Electrolytes KIMS), raw/labs/Ishamma T M 4.pdf (2026-03-02 Comprehensive panel KIMS), raw/labs/Ishamma T M 5.pdf (2026-02-25 CBC KIMS), raw/labs/Ishamma T M 6.pdf (2026-02-10 CBC+Electrolytes KIMS), raw/labs/Ishamma T M 7.pdf (2026-01-31 CBC+Electrolytes KIMS)
• KEY FINDINGS:
• LFTs EXIST — Critical gap resolved. Two LFT panels were embedded in multi-panel reports that the first pass only extracted CBC from:
  • 2026-01-19 (Ishamma T M 1 7.pdf): "Hepatic Panel 2" — TBil 0.4, DBil 0.2, ALT 14, AST 19, ALP 77, TP 7.6, Alb 4.4, Glob 3.2 — ALL NORMAL.
  • 2026-03-02 (Ishamma T M 4.pdf): "Hepatic Panel 1" — TBil 0.3, DBil 0.2, ALT 11, AST 16, ALP 60 — ALL NORMAL.
  • The overview statement "LFTs: All normal (no hepatotoxicity)" is now verified with source documents. No DILI despite 3 hepatotoxic meds.
• Hypomagnesemia — Magnesium 1.4 mg/dL (LOW, ref 1.60–2.60) on 2026-03-02. Only measured once. Clinically significant: can worsen hyponatremia, increase cardiac risk, and cause muscle weakness in an 81-year-old.
• Transient hypercalcemia — Calcium 10.7 mg/dL (HIGH, ref 8.60–10.20) on 2026-01-19. Normalized to 9.9 by 2026-03-02. Possibly related to bone turnover from AML marrow involvement.
• Creatinine stability confirmed — 0.62 (Jul 2025) → 0.8 (Jan 2026) → 0.7 (Mar 2026). Normal renal function maintained throughout AML treatment.
• Lipid panel #2 — 2026-03-02 (random): TC 173, TG 131, HDL 62.6, LDL 98, VLDL 26, TC/HDL 2.8. Mildly worsened from Jul 2025 but still optimal.
• Extensive electrolyte data fill — 7 potassium, 5 chloride, 7 bicarbonate data points that were missing from prior refine passes.
• RBC/MCV/RDW data fill — 4 RBC, 5 MCV, 7 RDW data points missing from prior passes.
• Authorizer identified — Greeshma M Nair MSc Medical Biochemistry authorized the Mar 2 comprehensive panel.
• New pages created (2):
• Lft — Liver function tests. 2 data points: Jan 19 (Hepatic Panel 2, full) and Mar 2 (Hepatic Panel 1, abbreviated). Both entirely normal. Resolves #1 gap from QoL analysis.
• Magnesium — 1 data point: 1.4 mg/dL (LOW). Hypomagnesemia flagged with warning callout.
• Existing pages enriched:
• Calcium — Added 2 data points: Jan 19 (10.7, H), Mar 2 (9.9, N). Now 3 data points. Reference range corrected to 8.60–10.20. Warning callout for transient hypercalcemia.
• Creatinine — Added 2 data points: Jan 19 (0.8), Mar 2 (0.7). Now 3 data points.
• Lipid Panel — Added Mar 2 data point. Now 2 data points with comparison analysis.
• Potassium — Added 7 data points: Apr 13 (4.8), Mar 30 (4.8), Mar 5 (4.7), Mar 2 (4.9), Feb 10 (4.4), Jan 31 (3.9), Jan 19 (4.7). Now 13 data points.
• Chloride — Added 5 data points: Mar 30 (94), Mar 5 (97), Mar 2 (96), Feb 10 (96), Jan 31 (97). Now 15 data points.
• Bicarbonate — Added 7 data points: Apr 13 (27.2), Mar 30 (28.6), Mar 5 (23.9), Mar 2 (27.4), Feb 10 (27.1), Jan 31 (26.3), Jan 19 (26.4). Now 12 data points.
• Rbc Count — Added 4 data points: Mar 5 (3.18), Mar 2 (3.47), Feb 10 (3.31), Jan 31 (2.72). Now 19 data points.
• Mcv — Added 5 data points: Mar 5 (94.0), Mar 2 (93.1), Feb 25 (92.4), Feb 10 (95.5), Jan 31 (94.1). Now 20 data points.
• Rdw — Added 7 data points: Mar 30 (17.8), Mar 5 (17.3), Mar 2 (17.3), Feb 25 (17.2), Feb 10 (17.6), Jan 31 (18.3), Jan 19 (19.4 — new highest recorded). Now 20 data points.
• Overview — LFT section verified with source docs. Creatinine updated to 0.7 (Mar 2). Added magnesium, calcium details. Added hypomagnesemia to Key Concerns (#6).
• Lab Trends — Updated potassium (most recent 4.8, Apr 13), bicarbonate (most recent 27.2, Apr 13), calcium (3 pts with H flag), creatinine (3 pts), added LFT, magnesium, lipid panel rows. Updated summary with LFT, magnesium, calcium trend, renal function, and lipid comparisons.
• Lab Timeline — Enriched 7 entries with electrolyte data. Upgraded Jan 19 to comprehensive panel (LFT+Ca/Cr). Upgraded Mar 2 to comprehensive panel (LFT+lipids+Ca/Mg/Cr).
• Index — Added 2 new pages, updated 8 data point counts. Page count 67→69.
• Hot — LFT gap marked RESOLVED. Added magnesium/calcium/LFT to latest labs. Added batch 5 refinement note.
• Inaccuracies corrected:
• Creatinine in overview: "0.6 mg/dL" → "0.7 mg/dL (2026-03-02)" — the 0.6 was from Jul 2025 Devi Scans; the most recent KIMS value is 0.7.
• RDW highest recorded: Was listed as 19.1% (Jan 16). Now correctly 19.4% (Jan 19) — previously missed from Ishamma T M 1 7.pdf.
• Verification notes:
• All 8 files had CBC data already in wiki — CBC values were NOT re-extracted (verified to match).
• Ishamma T M 5.pdf (Feb 25) — CBC only, no electrolytes. No new data.
• Ishamma T M 4.pdf (Mar 2) — the richest report in this batch: CBC + HbA1c + Creatinine + Electrolytes + Calcium + Magnesium + LFT + Lipid Panel. Previously only CBC and HbA1c were captured.
• Ishamma T M 1 7.pdf (Jan 19) — also rich: CBC + LFT + Electrolytes + Calcium + Creatinine. Previously only CBC was captured.

2026-04-17 (Refine — batch 6, 6 source files)

• Action: /refine pass
• Sources re-read: raw/labs/Ishamma T M 8.pdf (2026-01-25 CBC+Electrolytes KIMS), raw/labs/Ishamma T M 9.pdf (2026-01-22 CBC+Creatinine+Calcium KIMS), raw/labs/ISHAMMA T M (MR000384802).pdf (2025-11-22 Oncomine Myeloid Assay NGS, Agilus Diagnostics), raw/labs/Ishamma T M.pdf (2026-04-06 CBC+LFT+Electrolytes+Renal KIMS), raw/labs/Report For Accession No 4170ZB001398_MYSRLIN.pdf (2026-02-23 CBC+ESR DDRC Agilus), raw/labs/WhatsApp Scan 2025-11-26 at 19.58.39.pdf (2025-11-20 BMBx histopathology KIMS)
• KEY FINDINGS:
• 3rd LFT panel discovered (2026-04-06). Ishamma T M.pdf was previously captured as "CBC only" — it actually contains a full Hepatic Panel 2 (TBil 0.2, DBil 0.1, ALT 11, AST 15, ALP 63, TP 7.3, Alb 4.4, Glob 2.89 — all normal) plus Renal Panel (BUN 13.4, Cr 0.6) and full Electrolyte Panel (Na 132, K 4.4, Cl 93, HCO3 24.5). LFT monitoring now extends to 4 months of therapy with no hepatotoxicity.
• Calcium self-resolution documented. Jan 22 calcium was 10.1 mg/dL — showing rapid normalization just 3 days after the 10.7 peak (Jan 19). Confirms the hypercalcemia was truly transient.
• Creatinine 5th data point (0.9, Jan 22). Highest recorded value but still well within normal. Full range now documented: 0.6–0.9 mg/dL.
• Oncomine NGS report deeply enriched. Full genomic loci, MANE Select transcript IDs, variant allele frequencies, AMP/ASCO/CAP tier rationale, integrated molecular summary, assay QC metrics (coverage 3345x, uniformity 99.54%), analytical sensitivity (≥5% VAF), lab details (Agilus Diagnostics, Gurugram), and reviewing pathologists added to AML page. RUNX1 identified as preferred MRD marker.
• Feb 23 DDRC report enriched. RBC 3.37, MCV 97.7, MCH 32.1 (H), RDW 16.8, ALC 870 (L), AMC 50 (L) — all missing from previous passes. Platelet comment "rechecked on smear" noted. Lab: DDRC Agilus, reported by Dr. Vaishali Rajan.
• BMBx #1 timing details. Authorization dates confirmed: sample generated 2025-11-20 13:09, accepted 14:49, billed 12:50, authorized 2025-11-26 10:48 (6-day turnaround). Follow-up links added to subsequent procedures.
• Electrolyte data fill from Jan 25 (K 4.5, Cl 100, HCO3 25.1) and Apr 6 (K 4.4, HCO3 24.5). Notable: Jan 25 chloride was 100 (normal) — one of only 3 normal chloride values.
• Existing pages enriched:
• Lft — Added 3rd data point (Apr 6). Now 3 panels, all normal. Duration updated to "4+ months."
• Creatinine — Added 2 data points: Jan 22 (0.9), Apr 6 (0.6). Now 5 data points.
• Calcium — Added Jan 22 (10.1). Now 4 data points. Self-resolution of hypercalcemia documented.
• Urea — Added Apr 6 BUN (13.4). Now 2 data points. Note on different assays (urea vs BUN).
• Potassium — Added 2 data points: Jan 25 (4.5), Apr 6 (4.4). Now 15 data points.
• Chloride — Added Jan 25 (100, normal). Now 16 data points.
• Bicarbonate — Added 2 data points: Jan 25 (25.1), Apr 6 (24.5). Now 14 data points.
• Rbc Count — Added 3 data points: Jan 25 (2.85), Jan 22 (3.14), Feb 23 (3.37). Now 22 data points.
• Mcv — Added 3 data points: Jan 25 (96.5), Jan 22 (96.8), Feb 23 (97.7). Now 23 data points.
• Rdw — Added 3 data points: Jan 25 (18.3), Jan 22 (18.8), Feb 23 (16.8). Now 23 data points.
• Aml — Major enrichment of Oncomine molecular profile section: genomic loci, transcript IDs, variant interpretation summaries, integrated molecular summary, lab/QC details, reviewing pathologists.
• Bone Marrow Biopsy 2025 11 20 — Added authorization timeline, follow-up links to subsequent procedures and NGS.
• Lab Timeline — Upgraded Apr 6 entry to comprehensive panel (LFT+Renal+Electrolytes). Enriched Jan 25 and Jan 22 entries. Enriched Feb 23 entry with RBC indices and cell counts. Added Nov 22 NGS entry.
• Lab Trends — Updated creatinine (most recent 0.6, Apr 6), calcium (Jan 22 resolution noted), LFT (3 panels), urea (BUN, Apr 6).
• Overview — Updated creatinine (0.6, Apr 6, 5 data points), LFT (3 source docs), calcium (Jan 22 resolution), BUN added.
• Index — Updated 10 data point counts. Updated LFT description.
• Verification notes:
• Ishamma T M 8.pdf (Jan 25) — CBC already in wiki (Hb 8.7, WBC 5900, Plt 224, ANC 4670). Electrolytes missing — now added.
• Ishamma T M 9.pdf (Jan 22) — CBC already in wiki (Hb 9.6, WBC 6800, Plt 257, ANC 5410). Creatinine 0.9 and Calcium 10.1 missing — now added.
• ISHAMMA T M (MR000384802).pdf (Oncomine) — Variant table was in wiki but lacked genomic loci, transcript IDs, and detailed interpretations. Deep enrichment performed.
• Ishamma T M.pdf (Apr 6) — CBC already in wiki. LFT, BUN, Cr, and electrolytes missing — now added. This was the richest unextracted data in this batch.
• Report For Accession No 4170ZB001398 (Feb 23 DDRC) — Hb, WBC, Plt, ANC, ESR already in wiki. RBC, MCV, MCH, RDW, ALC, AMC missing — now added.
• WhatsApp Scan 2025-11-26 (BMBx #1) — Page existed with all key findings. Authorization dates and follow-up links added.
• No inaccuracies corrected — all existing data was correct.

2026-04-17 (Query — MRD targets explained)

• Query: "What is an MRD target, what's the importance"
• Action: Answered from Aml molecular profile. Filed synthesis → Mrd Targets Explained.
• Key points: RUNX1 is the preferred leukemia-specific MRD marker (per Agilus NGS report). ASXL1/SRSF2 are unreliable as sole MRD targets due to CHIP prevalence in elderly.
• Gap flagged: No molecular MRD testing has been performed or documented. Recommend discussing NGS-based MRD assessment (tracking RUNX1 VAF) with Dr. Bijay at next response assessment.
• Pages updated: Index (+1 synthesis), Hot (last query).

2026-04-17 (Query — RUNX1 MRD value without transplant)

• Query: "If transplant is not an option due to age, what's the purpose of doing RUNX1 as a MRD target?"
• Action: Answered from Mrd Targets Explained and Aml. Updated synthesis page with new section on non-transplant MRD utility.
• Key points: MRD monitoring with RUNX1 remains valuable even without transplant: (1) guides treatment intensity/duration on indefinite Aza-Ven, (2) early relapse detection before morphologic relapse, (3) confirms molecular depth of response beyond morphology, (4) distinguishes leukemia-specific signal from age-related CHIP persistence.
• Gap persists: No molecular MRD testing documented. Recommend discussion with Dr. Bijay.
• Pages updated: Mrd Targets Explained (+1 section), Hot (last query), Log.

2026-04-17 (Correction — Pegfilgrastim cycle timing)

• Query: "check Pegfilgrastim, it was given on cycle 3 not cycle 2 as is written"
• Action: Re-read WhatsApp source (raw/assets/2026-04-15_photo_033816.jpg). Dr. Bijay's Mar 30 message says "will avoid this time" (referring to Cycle 4+), confirming pegfilgrastim was given during Cycle 3 (started 2026-03-02), not Cycle 2. Previous wiki entries had incorrectly assigned it to Cycle 2.
• Pages updated: Pegfilgrastim (date_started 2026-01-19→2026-03-02, clinical course rewritten), Aml (cycle table and G-CSF section corrected), Hot (cycle history corrected).
• Note: The ANC nadir of 610 on 2026-02-17 occurred during Cycle 2, unrelated to pegfilgrastim.

2026-04-17 (Query — Top 10 QoL interventions)

• Query: "top 10 things to do to improve quality of life"
• Action: Expanded previous 5-item QoL synthesis to top 10. Read Profile, Overview, Hot, Aml, Active Medications, Hyponatremia, Magnesium, Allergy List.
• New items added: #3 Hypomagnesemia evaluation, #4 Fall prevention, #6 Nutritional optimization, #8 Immunization records, #9 Sleep assessment, #10 Treatment milestones. Original items reorganized and updated.
• Gaps flagged: No dietary/nutritional data, no sleep documentation, immunization record empty, hyponatremia workup never ordered, Mg measured only once, transfusion reaction type unknown, no home safety assessment, no molecular MRD testing.
• Pages updated: Qol Bang For Buck (rewritten, expanded to top 10), Log, Hot.

2026-04-17 (Ingest — Herpes zoster history and zoster vaccine)

• Source: Patient report via Sameer Badarudeen (son). Saved as raw/clinic-notes/2026-04-17_patient-report_zoster-history.md.
• Content: Patient had prior history of herpes zoster (shingles). Zoster vaccine given approximately 10 years ago (~2016, presumed Zostavax).
• Pages created: Herpes Zoster (condition, resolved), raw/clinic-notes/2026-04-17_patient-report_zoster-history.md (raw source)
• Pages updated: Immunization Record (first vaccine entry added), Acyclovir (prior VZV reactivation history callout), Profile (resolved conditions section added), Index (herpes-zoster added to resolved conditions, page/source counts updated), Preventive Schedule (Zostavax entry added, Shingrix recommendation updated), Hot (immunization gap partially resolved), Log
• Clinical significance: Prior VZV reactivation + current immunosuppression = high reactivation risk. Acyclovir prophylaxis is even more critical. Zostavax efficacy has likely waned after ~10 years. Shingrix should be discussed once immunosuppression resolves.

2026-04-19 (Query — Counter-intuitive insights)

• Query: "show me some counter intuitive insights from this data about this patient"
• Pages created: Counter Intuitive Insights (synthesis)
• Pages updated: Index (synthesis added, page count 71→72), Log
• Key findings: 8 counter-intuitive patterns identified: (1) HbA1c improvement is likely artifactual due to RBC turnover, (2) liver function suspiciously resilient on 3 hepatotoxic drugs, (3) fall risk is more immediately dangerous than the cancer, (4) 2022 inflammatory episode may have been early signal of dysplastic clone, (5) pegfilgrastim discontinuation may be biologically correct for NRAS-mutated AML, (6) sodium diverges from the recovery trend — treatment-driven not disease-driven, (7) positive ANA was clinically meaningless but triggered invaluable workup, (8) posaconazole is a deliberate pharmacokinetic/cost hack.
• Gaps flagged: No fructosamine/glycated albumin, no pharmacogenomic testing, 2022 episode undiagnosed, hyponatremia workup never ordered, no home safety assessment.

2026-04-19 (Query — 2022 inflammatory episode source labs)

• Query: "In September 2022, she had CRP 128 mg/L, ESR 119, WBC 14,770, and IgE 203 ... where is the source lab report"
• Answer: Two source reports identified: raw/labs/4182VI0091894182_910394a.pdf (2022-09-20, peak inflammation) and raw/labs/4182VI0131054182_816476x.pdf (2022-09-27, resolving). Peak markers from Sept 20; platelets 501K and Hb 11.0 from Sept 27 follow-up.
• Pages created: 2022 Inflammatory Episode Clonal Evolution (synthesis — connects 2022 proliferative phenotype to 2025 AML failure phenotype)
• Pages updated: Index (synthesis added, page count 72→73), Hot (gap noted: 2022 episode etiology still undiagnosed), Log

2026-04-19 (Query — CYP3A4 metabolizer status and venetoclax implications)

• Query: "Hepatic resilience in an 81-year-old is genuinely unusual — is she a favorable CYP metabolizer, and what are the implications for venetoclax drug levels?"
• Answer: If Ishamma is a CYP3A4 rapid metabolizer, the posaconazole-venetoclax dose-reduction strategy may produce lower-than-expected venetoclax exposure (2–4x increase vs expected 5–8x). Treatment is currently working (morphologic response, count recovery), but subtherapeutic venetoclax levels could compromise remission durability in this adverse-risk patient. Recommended: venetoclax trough levels, posaconazole trough levels, and/or CYP3A4 pharmacogenomic testing.
• Filed: Cyp3A4 Metabolizer Venetoclax Implications
• Gap flagged: No drug level monitoring (venetoclax or posaconazole troughs) in any ingested raw documents.

2026-04-19 (Query — Medication list)

• Query: "medication list"
• Answer: Retrieved current medication list from Active Medications. 4 active medications: azacitidine (AZA 5 days IV per cycle), venetoclax (VEN 5 days per cycle, dose reduced due to posaconazole interaction), acyclovir (antiviral prophylaxis), posaconazole (antifungal prophylaxis + pharmacokinetic booster). 1 discontinued: pegfilgrastim (G-CSF, stopped 2026-03-30 due to severe bone pain).
• Note: Simple retrieval query — no synthesis needed. Medication details fully documented in Active Medications, individual medication pages exist for all drugs.
• Gap: Exact doses remain unknown (no prescription documents ingested). Non-oncology medications (e.g., diabetes management) not documented.

2026-04-19 (Query — Medication list, deep search writeback)

• Query: "medication list"
• Answer: Retrieved current medication list from Active Medications. 4 active medications: azacitidine (AZA 5 days IV per cycle), venetoclax (VEN 5 days per cycle, dose reduced 50–100 mg due to posaconazole interaction), acyclovir (antiviral prophylaxis), posaconazole (antifungal prophylaxis + pharmacokinetic booster). 1 discontinued: pegfilgrastim (G-CSF, stopped 2026-03-30 due to severe bone pain).
• Note: Simple retrieval query — no synthesis needed. Medication details fully documented in Active Medications, individual medication pages exist for all drugs.
• Gap: Exact doses remain unknown (no prescription documents ingested). Non-oncology medications (e.g., diabetes management, supportive care beyond acyclovir/posaconazole) not documented.

2026-04-19 (Query — Cytogenetics, writeback)

• Query: "cytogentics" [sic]
• Answer: Karyotype 46,XX[10] (normal female karyotype, 10 cells analyzed, 2025-11-29, DDRC Agilus). No numerical or structural chromosomal abnormalities detected. Despite normal cytogenetics, patient classified as adverse-risk AML due to molecular profile (RUNX1, ASXL1, SRSF2 mutations override favorable karyotype per ELN 2022). Demonstrates complementarity of cytogenetics (detects large chromosomal changes) vs molecular genetics (detects gene-level mutations). No synthesis filed (straightforward retrieval from Karyotype 2025 11 29 and Aml).
• Gap noted: No FISH testing documented (would detect cryptic rearrangements missed by conventional karyotyping, though unlikely to change management given clear molecular drivers).
• Writeback: Query logged to wiki/log.md. No synthesis created (straightforward fact retrieval, no new analysis). No gaps identified beyond previously noted FISH testing.

2026-04-19 (Query — Treatment Regimen Assessment)

• Query: "How do you rate overall current treatment regimen as documented in the wiki"
• Answer: Regimen (Aza-Ven) is guideline-concordant and showing measurable response (Day 21 BMBx response, Hb 6.8→10.5, WBC normalizing, ESR 130→40). Supportive care appropriate. However, significant monitoring/documentation gaps: no drug levels measured, no MRD testing, exact doses unknown, venetoclax duration reduction rationale undocumented, hyponatremia/hypomagnesemia unworked-up, no response assessment schedule. Filed synthesis → Treatment Regimen Assessment.
• Pages updated: index.md, log.md, hot.md
• Pages created: Treatment Regimen Assessment

2026-04-19 (Query — Vasopressin Receptor Antagonist Assessment)

• Query: "What would be an ideal vasopressin receptor antagonist for her?"
• Answer: Neither tolvaptan nor conivaptan can be safely used — both are CYP3A4 substrates, and Ishamma is on posaconazole (strong CYP3A4 inhibitor) as part of the venetoclax dose-reduction strategy. Tolvaptan is FDA-contraindicated with strong CYP3A4 inhibitors. For her mild hyponatremia (Na 129–135), fluid restriction + salt supplementation + magnesium correction are safer first-line approaches. SIADH workup (serum/urine osm, urine Na) still missing. Filed synthesis → Vaptan Assessment.
• Pages updated: index.md, log.md, hot.md
• Pages created: Vaptan Assessment

2026-04-19 (Query — Medication Cessation Risk Assessment)

• Query: "What would happen if I stopped taking all medications tomorrow?"
• Answer: Comprehensive risk assessment of stopping all 4 active medications (azacitidine, venetoclax, posaconazole, acyclovir). Medications form an interlocking system — Aza-Ven controls leukemia, posaconazole dual-purposed for infection prevention + VEN boosting, acyclovir prevents viral reactivation. Stopping all would lead to AML relapse (weeks-months), invasive fungal infection risk (immediate), VZV reactivation risk (days-weeks). Compounded by age 81, adverse-risk molecular profile, no G-CSF backup, and unknown non-oncology medications. Filed synthesis → Medication Cessation Risk Assessment.
• Pages updated: index.md, log.md, hot.md
• Pages created: Medication Cessation Risk Assessment

2026-04-19 (Query — Normal Liver vs Vaptan Eligibility)

• Query: "Since liver is normal, is vaptan not an option?"
• Answer: Normal LFTs reduce one risk factor (tolvaptan hepatotoxicity) but do NOT remove the primary contraindication: posaconazole (strong CYP3A4 inhibitor) blocks metabolism of both tolvaptan and conivaptan. FDA contraindication is CYP3A4-based, not liver-function-based. Normal liver is a favorable baseline but irrelevant while posaconazole is on board. Referred to existing Vaptan Assessment synthesis. No new synthesis created (clarification of existing analysis).
• Pages updated: log.md, hot.md

2026-04-19 (Query — Summarize most recent changes)

• Query: "Summarize the most recent changes"
• Answer: Summary of vault activity across Apr 17–19. Apr 19: 12+ queries producing 6 new synthesis pages (treatment assessment, vaptan assessment, CYP3A4 implications, medication cessation risk, 2022 clonal evolution hypothesis, counter-intuitive insights). Apr 17: 6-batch refine sprint resolving LFT gap (3 panels found), discovering hypomagnesemia, resolving 3 pending labs (SPEP, free light chains, copper), correcting pegfilgrastim timing, creating 12+ new lab pages. Wiki grew from 55→76 pages. No new synthesis created (informational summary).
• Pages updated: log.md

2026-04-19 (Query — SIADH Diet in Indian Context)

• Query: "diet changes in indian context to manage SIADH"
• Answer: Comprehensive dietary guidance for managing presumed SIADH in Kerala/Indian context. Four pillars: (1) Fluid restriction to 800–1000 mL/day — limit kanji, rasam, moru, tender coconut; prefer puttu, dosa, appam with thick curries. (2) Increase salt — salt tablets, pickles, upperi, pappadam. (3) Increase protein for solute load — fish curry, eggs, kadala, dal (thick preparations); BUN only 13.4, room for increase. (4) Magnesium-rich foods — muringa ila, ragi, ellu, banana, cashews. Includes sample Kerala day meal plan (~770 mL total fluid). Integrates with concurrent conditions: diabetes (HbA1c 5.7%, avoid excess sugar), AML/neutropenia (all food freshly cooked, no raw items during ANC nadirs), hypomagnesemia.
• Filed: Siadh Diet Indian Context
• Pages updated: index.md (synthesis added, page count 76→77), log.md, hot.md
• Gaps flagged: (1) SIADH not confirmed (no serum/urine osm, no urine Na), (2) Blood pressure not documented (salt loading contraindicated if hypertensive), (3) Height/weight/BMI unknown, (4) Current diet and appetite not documented, (5) No dietitian involvement documented.

2026-04-20 (Ingest — KIMS Lab Report, CBC + Electrolytes + Magnesium)

• Source: raw/labs/20260420_Ishamma T M today.pdf
• Document type: KIMS Health Laboratory Medicine report. Bill No L029731026. Billed 2026-04-20 10:53 (OP CASH). Ordering physician: Dr. Bijay Prabhakaran Nair. Authorized by: Greeshma M Nair, MSc Medical Biochemistry. Sample collected: 2026-04-20 02:25 PM.
• Panels: Electrolyte Panel (Serum) + Magnesium (Serum) + CBC (Blood)
• Key findings extracted:
• Electrolytes: Na 128 (L — NEW NADIR, prev 133 on Apr 13), K 4.7 (N), Cl 93 (L), HCO3 22.8 (N low end)
• Magnesium: 1.2 mg/dL (L — new low, prev 1.4 on Mar 2)
• CBC: Hb 11.4 (L ↑ from 10.5), WBC 4100 (N ↑ from 3500), Plt 99 (L — new concern, below 100K), ANC 2970 (N), RBC 3.62 (L), MCV 93.1 (H), MCH 31.5 (N), MCHC 33.8 (N), RDW 17.6 (H), MPV 9.9 (N)
• ALC 690 (L — lymphopenia). AEC 70 (N). AMC 340 (N). Basophils 20 (N).
• Abnormal flags: Na 128 (moderate hyponatremia — new nadir), Cl 93 (L), Mg 1.2 (L), Hb 11.4 (L), Plt 99 (L — thrombocytopenic, below 100K), RBC 3.62 (L), MCV 93.1 (H — macrocytic), RDW 17.6 (H — anisocytosis), ALC 690 (L — lymphopenia)
• Clinical significance: Na has dropped from 133 (Apr 13) to 128 (Apr 20) — new nadir, crossing into moderate hyponatremia (<130). Simultaneously, Mg has worsened from 1.4 (Mar 2) to 1.2 (Apr 20) — the Mg-Na relationship is clinically relevant as hypomagnesemia can impair sodium regulation. Platelets dropped from 140K to 99K — first time below 100K since March 2026. WBC and Hb both improved vs Apr 13.
• Wiki pages updated (12 lab marker pages + 3 meta pages + 2 tracking pages):
• Sodium — 17→18 data points; trend analysis updated for Na 128 new nadir
• Chloride — 16→17 data points
• Potassium — 15→16 data points
• Bicarbonate — 14→15 data points
• Magnesium — 1→2 data points; trend analysis updated (1.4→1.2 worsening)
• Hemoglobin — 23→24 data points; trend analysis updated
• Wbc — 24→25 data points; trend analysis updated (back to normal)
• Platelet Count — 23→24 data points; trend analysis + warning added (<100K)
• Anc — 22→23 data points; trend analysis updated
• Rbc Count — 22→23 data points
• Mcv — 23→24 data points
• Rdw — 23→24 data points
• Lab Trends — all key markers updated to Apr 20 values
• Lab Timeline — new row prepended for 2026-04-20
• Index — data point counts updated; sources 44→45; last ingest updated
• Pages created: 0 (all existing pages updated)
• No information contradicted existing wiki content.

2026-04-20 (Query — Non-hematology lab insights, latest panel)

• Query: "What are the insights from the latest labs apart from hematology"
• Answer source: wiki/labs/sodium, magnesium, potassium, chloride, bicarbonate, lft, creatinine, urea, hba1c; wiki/conditions/hyponatremia
• Filed synthesis: Non Hematology Labs Insights Apr2026
• Updated: Hyponatremia condition page (stale — still showed Na 134 trending normal; corrected to Na 128 new nadir, moderate hyponatremia)
• Key findings: Na 128 new nadir (moderate); Mg 1.2 worsening (progressive); Cl 93 persistent; HCO3 22.8 low-normal; K/LFT/Cr/BUN all stable; SIADH-type electrolyte pattern confirmed; 6 monitoring gaps identified (no LFT/Cr/Urine osm/ECG/Ca/Phos on Apr 20 panel)

2026-04-20 (Ingest — Clinic Note, raw/clinic-notes/2026-04-20_note.md)

• Source: raw/clinic-notes/2026-04-20_note.md
• Document type: Clinic note (single-sentence patient report)
• Key finding extracted: Patient was taking oral magnesium supplement but ran out approximately 2 weeks prior to the Apr 20 visit (~2026-04-06).
• Clinical significance: This is a previously undocumented medication. The supplement lapse (~Apr 6) directly precedes the new Mg nadir (1.2 mg/dL, Apr 20 — down from 1.4 on Mar 2). Lapse is NOT a clinical discontinuation — supply ran out. Mg must be resumed or escalated. Concurrent with Na 128 (new nadir): hypomagnesemia can worsen SIADH-type hyponatremia.
• Contradiction resolved: Mg worsening (1.4 → 1.2) previously unexplained by lab data alone. Now explained by supplement lapse.
• Pages created (1):
• Magnesium Oral — New medication page documenting oral Mg supplement, lapse date, clinical context, action needed
• Pages updated (5):
• Magnesium — Trend analysis updated with supplement lapse context and link to Magnesium Oral
• Active Medications — Oral Mg added to Discontinued table with urgency note
• Hyponatremia — Mg depletion as contributing factor to Na decline now explicitly documented
• Index — New page added, raw sources 45→46, pages 78→79
• Hot — Pending/Gaps and Last Ingest sections updated
• Raw sources ingested: 46 total (was 45)
• Pages: 79 total (was 78)

2026-04-20 (Query — Oral Mg glycinate maximum prescription dosage)

• Query: "Oral Mg glycinate what should be the prescription dosage maximum oral"
• Answer: Pharmacological reference: start 200 mg elemental Mg b.i.d. (400 mg/day); escalate to 400 mg b.i.d. (800 mg/day) if no normalization in 1–2 weeks; absolute maximum 400 mg t.i.d. (1200 mg/day); practical elderly ceiling 400–600 mg/day. GI-limited single-dose ceiling ~300–350 mg. IV MgSO₄ 1–2 g q6–8h if oral insufficient. Glycinate preferred (80% bioavailability, PepT1 absorption, neutral pH — no posaconazole interaction).
• Filed: Magnesium Glycinate Oral Dosing
• Gap: Actual dose prescribed to Ishamma still unknown — no Rx record ingested.
• Synthesis filed: No (gap query, insufficient data to file)

2026-04-27 (Ingest — KIMS Lab Report, raw/labs/20260427_Ishamma T M 1 ok.pdf)

• Source: raw/labs/20260427_Ishamma T M 1 ok.pdf
• Document type: KIMS Health Laboratory Medicine — CBC + Electrolyte Panel + Magnesium
• Bill No: L031606726 (OP CASH)
• Ordering physician: Dr. Bijay Prabhakaran Nair
• Sample collected: 2026-04-27 at 01:33 PM
• Authorized: 01:58 PM (CBC), 02:44–02:50 PM (electrolytes/Mg)
• Pages created: None (all existing pages updated)
• Pages updated (12): Hemoglobin, Wbc, Anc, Platelet Count, Rbc Count, Mcv, Rdw, Sodium, Potassium, Chloride, Bicarbonate, Magnesium
• Meta pages updated (4): Lab Trends, Lab Timeline, Index, Log
• Hot cache updated: yes (Apr 27)
• Source count: 46 → 47

Key Findings (Apr 27 vs Apr 20)

Clinical Interpretation

• Lineage-dissociated kinetics: Platelets recovered strongly (99K → 196K) while WBC/ANC dropped simultaneously. This is consistent with treatment cycle timing — different marrow lineages recovering at different rates.
• Electrolyte stabilization: Na improved 6 points (128 → 134) and Mg recovered to prior baseline (1.4). Both concurrent — Mg replenishment may have aided Na handling. SIADH workup still outstanding.
• No new conditions or diagnoses: No contradictions with existing wiki content identified.
• Mg supplement: The Apr 27 Mg improvement to 1.4 strongly suggests supplementation was resumed following the Apr 20 clinic visit. Still below normal range; escalation should be discussed.

2026-04-29 (Ingest — Dr Lal PathLabs Fructosamine Report, raw/labs/2026-04-29_ISHAMMA.pdf)

• Source: raw/labs/2026-04-29_ISHAMMA.pdf
• Document type: Dr Lal PathLabs National Reference Laboratory — Serum Fructosamine
• Lab No: 515013880
• Ordering physician: Dr. Bijay Prabhakaran Nair
• Collected: 2026-04-22 at 09:19 AM (KIMS Health)
• Processed: Dr Lal PathLabs National Reference Laboratory, Block E, Sector 18, Rohini, New Delhi
• Reported: 2026-04-23 at 04:50 PM
• Pages created (1): Fructosamine
• Pages updated (2): Diabetes Mellitus, Hba1C
• Meta pages updated (4): Lab Trends, Lab Timeline, Index, Log
• Source count: 47 → 48
• Page count: 79 → 80

Key Finding — HbA1c-Fructosamine Discordance

Fructosamine 310 µmol/L (HIGH) — reference range 122–236 µmol/L.

This result contradicts the improving HbA1c trend documented in the wiki:
- HbA1c: 6.8% (Nov 2025) → 5.7% (Mar 2026) — appeared to improve into pre-diabetic range
- Fructosamine: 310 µmol/L (Apr 2026) — elevated, indicates poor short-term glucose control (1–2 weeks)

Clinical Interpretation

The HbA1c improvement is likely spurious, caused by:
1. Altered RBC turnover from azacitidine/venetoclax treatment
2. Shorter RBC lifespan in active AML
3. Transfusion dilution (if transfusions given)

Fructosamine measures glycated serum proteins (primarily albumin) and is not affected by red cell turnover, hemolysis, or transfusions. This makes it the more reliable glycemic marker in patients with hematologic malignancy.

Conclusion

True diabetes likely persists with poor control despite the "improving" HbA1c. The patient's albumin is normal (4.4 g/dL), so fructosamine should be reliable. This result strongly suggests:
- Diabetes is still active
- Glucose control is suboptimal
- HbA1c should not be used as the primary glycemic marker going forward
- Consider home glucose monitoring and diabetes-specific medication (none currently documented)

Pages Modified

1. Fructosamine — Created. First fructosamine measurement, value 310 µmol/L (HIGH). Documents HbA1c-fructosamine discordance and interpretation.
2. Diabetes Mellitus — Updated. Added fructosamine to related_labs. Rewrote clinical summary and trend analysis to highlight HbA1c unreliability. Added glycemic monitoring comparison table. Updated related section to prioritize fructosamine.
3. Lab Trends — Added fructosamine row to key markers table. Updated metabolic summary to include fructosamine finding and HbA1c unreliability warning.
4. Lab Timeline — Added 2026-04-22 entry for fructosamine test.

No Contradictions Detected

This finding does not contradict existing wiki content — it clarifies the existing HbA1c trend by identifying it as unreliable. The wiki already noted HbA1c might be affected by AML treatment (Diabetes Mellitus:36-39, Hba1C:22-24). This fructosamine result confirms that suspicion.

2026-04-29 (Query — Days to next chemo)

• Question: How many days to next chemo?
• Answer: Next cycle date not documented. Cycle 4 Day 1 was 2026-04-06. Based on observed inter-cycle intervals (35–41 days), Cycle 5 estimated 2026-05-04 to 2026-05-17 (5–18 days away as of Apr 29). ANC gating: ANC 1990 on Apr 27 (mild neutropenia) — cycle likely held until ANC ≥ 2000–2500. Gap: No Cycle 5 appointment record in vault.
• Action: Gap flagged. No synthesis filed (insufficient data for meaningful analysis). Log entry added.

2026-04-29 (Query — Incomplete: "Taking this now")

• Question: "Taking this now" — no medication or substance named; query was incomplete.
• Answer: Could not answer; asked user to clarify what substance "this" refers to. Suggested dropping a new prescription into raw/prescriptions/ and running /ingest if a new document is available.
• Action: No wiki changes made. No synthesis filed.

2026-04-29 (Ingest — Clinic Note, raw/clinic-notes/2026-04-29_note.md)

• Source: raw/clinic-notes/2026-04-29_note.md
• Document type: Clinic note (brief)
• Content: Single-line note: "taking renerve once daily"
• Extraction:
• New medication documented: Renerve — Methylcobalamin (B12) + Pyridoxine (B6) + Alpha Lipoic Acid + Folic Acid combination (Indian brand neurological supplement). Dose: 1 tablet once daily oral. Prescriber not stated in note.
• Renerve was not previously documented in the vault. First appearance of this medication.
• Pages created (1): Renerve (wiki/medications/renerve.md)
• Pages updated (3): Active Medications (added Renerve row), Profile (added to active medications section), Index (added renerve entry, source/page counts updated)
• Health picture change: Moderate — previously unknown supportive medication now documented. No new diagnoses or lab findings.
• Gaps surfaced: Renerve start date unknown. Prescriber unknown. Exact variant not confirmed. No serum B12 baseline in vault.

2026-04-29 (Ingest — Clinic Note, raw/clinic-notes/20260429_124418_note.md)

• Source: raw/clinic-notes/20260429_124418_note.md
• Document type: Clinic note (brief, single-line)
• Content: "taking renerve once daily"
• Assessment: This is a second Apr 29 clinic note corroborating the same information already captured from raw/clinic-notes/2026-04-29_note.md (the primary Renerve documentation note, ingested earlier today). No new clinical information. No new conditions, labs, or medication changes.
• Pages created (0): None — Renerve already existed
• Pages updated (2): Renerve (added source reference), Active Medications (updated renerve row note)
• Meta pages updated (3): Index, Log, Hot
• Source count: 49 → 50
• Page count: 81 (unchanged)

2026-04-29 (Backfill Sources — wiki/conditions/)

• Task: Backfill missing sources in condition pages
• Files processed: 9 condition files
• Files updated: 0
• Result: All 9 condition files already have populated sources arrays. No backfill needed.
• Files checked:
• wiki/conditions/aml.md (14 sources)
• wiki/conditions/anemia.md (3 sources)
• wiki/conditions/diabetes-mellitus.md (4 sources)
• wiki/conditions/elevated-esr.md (1 source)
• wiki/conditions/herpes-zoster.md (1 source)
• wiki/conditions/hyponatremia.md (2 sources)
• wiki/conditions/jothydev-clinic-note-2022-11-25.md (7 sources)
• wiki/conditions/pancytopenia.md (4 sources)
• wiki/conditions/positive-ana.md (1 source)

2026-04-29T15:10:12Z (Backfill Sources — wiki/procedures/)

• Task: Backfill missing sources in procedure pages
• Files processed: 6 procedure files
• Files updated: 4
• Result: Updated sources arrays with correct raw/ paths wrapped in wikilinks
• Log entries:
• 2026-04-29T15:10:12Z backfill-sources: wiki/procedures/bone-marrow-biopsy-2025-11-20.md -> sources updated to Raw/Labs/Whatsapp Scan 2025 11 26 At 19.58.39.Pdf
• 2026-04-29T15:10:12Z backfill-sources: wiki/procedures/bone-marrow-biopsy-2025-11-28.md -> sources already correct (raw/clinic-notes)
• 2026-04-29T15:10:12Z backfill-sources: wiki/procedures/bone-marrow-biopsy-2025-12-31.md -> sources updated to Raw/Labs/Ishamma T M 11.Pdf
• 2026-04-29T15:10:12Z backfill-sources: wiki/procedures/flow-cytometry-2025-11-28.md -> sources updated to Raw/Labs/File2000384802.Pdf
• 2026-04-29T15:10:12Z backfill-sources: wiki/procedures/karyotype-2025-11-29.md -> sources updated to Raw/Labs/Ishamma.Pdf
• 2026-04-29T15:10:12Z backfill-sources: wiki/procedures/port-placement-2025-12-09.md -> sources already correct (raw/clinic-notes)
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/uric-acid.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/wbc.md -> 27 source(s) added

2026-04-29T15:07:58Z (Backfill Sources — wiki/labs/)

• Task: Backfill missing sources in lab marker pages
• Files processed: 39 lab marker files (excluding _lab-trends.md and _lab-timeline.md)
• Files updated: 39
• Result: All 39 lab marker files now have populated sources arrays extracted from body content and source references.
• Log entries:
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/ana.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/anc.md -> 23 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/anti-ccp.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/anti-dsdna.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/bicarbonate.md -> 16 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/calcium.md -> 4 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/ceruloplasmin.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/chloride.md -> 17 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/complement-c3.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/complement-c4.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/copper-serum.md -> 2 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/creatinine.md -> 6 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/crp.md -> 4 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/d-dimer.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/esr.md -> 6 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/fasting-blood-sugar.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/folic-acid.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/free-light-chains.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/fructosamine.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/hba1c.md -> 4 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/hemoglobin.md -> 26 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/iron-profile.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/lft.md -> 3 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/lipid-panel.md -> 2 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/magnesium.md -> 3 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/mcv.md -> 26 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/peripheral-smear-2025-11-17.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/peripheral-smear-2025-11-19.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/platelet-count.md -> 26 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/potassium.md -> 18 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/rbc-count.md -> 24 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/rdw.md -> 25 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/reticulocyte-count.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/sodium.md -> 20 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/spep.md -> 1 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/total-ige.md -> 2 source(s) added
• 2026-04-29T15:07:58Z backfill-sources: wiki/labs/urea.md -> 3 source(s) added

2026-04-29T15:13:22Z (Backfill Sources — wiki/syntheses/)

• Task: Backfill missing sources in synthesis pages
• Files processed: 12 synthesis files
• Files updated: 12
• Result: All 12 synthesis files now have populated sources arrays extracted from wiki citations in body content.
• Log entries:
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/2022-inflammatory-episode-clonal-evolution.md -> 14 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/counter-intuitive-insights.md -> 20 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/cyp3a4-metabolizer-venetoclax-implications.md -> 7 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/magnesium-diet-kerala-context.md -> 10 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/magnesium-glycinate-oral-dosing.md -> 5 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/medication-cessation-risk-assessment.md -> 11 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/mrd-targets-explained.md -> 5 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/non-hematology-labs-insights-apr2026.md -> 15 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/qol-bang-for-buck.md -> 11 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/siadh-diet-indian-context.md -> 12 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/treatment-regimen-assessment.md -> 20 source(s) added
• 2026-04-29T15:13:22Z backfill-sources: wiki/syntheses/vaptan-assessment.md -> 10 source(s) added

2026-05-01 — Query: Daily Medications and Dosage

• Query: "Tell me more about daily medication and the dosage."
• Sources read: Active Medications, Azacitidine, Venetoclax, Acyclovir, Posaconazole, Renerve, Magnesium Oral
• Key finding: All 4 chemoprophylaxis medications (AZA, VEN, acyclovir, posaconazole) have UNKNOWN doses — no prescription documents ingested. Only Renerve (1 tab q.d.) and Mg-oral (supply lapsed) have any dose data. This is a persistent critical gap.
• Synthesis filed: No — this is a retrieval query (compilation of existing data, no new analysis).
• Gaps confirmed: No prescription PDFs in vault. Medication doses for all oncology drugs remain undocumented. Drop Rx or prescription slips into raw/prescriptions/ and run /ingest.

2026-05-01T00:00:00Z (Session Start — Greeting)

• Query: "hi" — session greeting, no medical content
• Action: Session loaded. No synthesis created (trivial query). No gaps identified.

2026-05-03T00:00:00Z — Query: NGS and MRD importance

• Query: "What's the importance of NGS and MRD"
• Sources read: Hot, Index, Aml, Mrd Targets Explained
• Answer: Synthesized NGS diagnostic role (mutation identification, WHO classification, ELN risk, target selection) and MRD role (depth of response, relapse prediction, treatment guidance) in the context of Ishamma's 6-mutation molecular profile. Key point: diagnostic NGS done (Nov 2025, Oncomine); NGS-MRD post-treatment not yet performed — now overdue at Cycle 4+.
• Created: Ngs And Mrd Importance
• Updated: Index
• Gap flagged: NGS-MRD with RUNX1 VAF tracking overdue; already in hot.md Pending. Recommend raising with Dr. Bijay at next visit.

2026-05-03 — Query Writeback: /lint

• Query: /lint
• Sources read: All 103 wiki pages (full structural audit)
• Answer: Full lint report — see Lint Report 2026 05 03 in wiki/queries/
• Created: Lint Report 2026 05 03
• Updated: Index, Log
• Gaps confirmed: ECG unordered (ANC+Mg in 81yo), fructosamine repeat due May 2026, DM medications undocumented, SIADH workup missing, imaging vault empty — all pre-existing, no new gaps introduced.

2026-05-03 — LINT: Full wiki audit

• Trigger: /lint (manual)
• Files scanned: 103 wiki pages (all types)
• Broken wikilinks: 0
• Orphan pages: 0
• Missing frontmatter: 0 (2 macOS system files ._hot.md / ._log.md excluded — not vault files)
• Schema violations: 1 (FIXED — see below)
• Stale data flagged: 3 items (see below)
• Preventive care overdue: 1 (fructosamine repeat — see below)

Issues Found and Fixed

1. FIXED — hyponatremia.md: Duplicate YAML sources key (invalid YAML) — Two sources: fields at lines 10 and 13 caused second entry to silently overwrite first, losing original source references. Merged into single field. Also updated condition page with Apr 27 Na 134 data point (was missing from condition table, present in Sodium page). Updated updated: to 2026-04-27.
2. FIXED — _preventive-schedule.md: Glycemic monitoring row outdated — Row referenced HbA1c as preferred marker with last result Mar 2. Updated to fructosamine as preferred marker (HbA1c invalid due to AML RBC turnover), with next fructosamine due ~May 2026. Date updated to 2026-05-03.
3. FIXED — index.md: Last lint date updated to 2026-05-03.

Issues Flagged (Human Review Required)

1. conditions/diabetes-mellitus.md — No DM medications listed — medications: [] in frontmatter. No diabetes-specific agent (metformin, insulin, GLP-1, SGLT2i) documented. Gap already noted in hot.md; fructosamine 310 confirms active DM. Confirm with treating team.
2. conditions/hyponatremia.md — SIADH workup outstanding — Still no urine osm, urine Na, or serum osm in vault. Documented as active gap. No auto-fix possible.
3. magnesium-oral.md — Dose/formulation unknown — dose: unknown per schema; supplement lapsed Apr 6, partial recovery seen Apr 27. Prescription required. Drop into raw/prescriptions/.
4. wiki/family-history/_family-history.md — Empty — No family history recorded. Clinically relevant for AML risk counseling. Source required.
5. wiki/dental/_dental-history.md — Empty — No dental records. Low priority given active oncology context.
6. wiki/insurance/_coverage-summary.md / _claims-tracker.md — Empty — No insurance documents ingested. Drop EOBs into raw/insurance/.
7. No imaging pages exist — Zero imaging studies ingested. Expected: CXR (port placement Dec 9), CT CAP, ECHO. Drop into raw/imaging/.
8. macOS system files ._hot.md / ._log.md — Present in wiki/. Not vault files. If vault is version-controlled, add ._* to .gitignore.

Preventive Care Overdue

• Fructosamine repeat — Last: 2026-04-22 (310 µmol/L, HIGH). Due ~May 2026 (4-week interval). Not yet in raw docs. Request at next clinic visit.
• ECG — ANC 1990 + Mg 1.4 in 81yo; no ECG on record. Should be ordered at next visit.

Stale Data Review

• All lab markers updated within past 90 days — none overdue (chemo-era monitoring active)
• Magnesium last point Apr 27 — within monitoring window
• Creatinine last point Apr 6 — 27 days ago, due at next CBC + chemistry panel

Summary: Wiki is in excellent structural health. 3 auto-fixes applied. 11 items flagged for human review or future ingestion.

2026-05-04 — INGEST: CBC + Electrolyte Panel (KIMS)

• Source: raw/assets/2026-05-04_Ishamma_T_M.pdf (KIMS Health, Bill L033433126)
• Document type: Lab results — Complete Blood Count + Electrolyte Panel + Magnesium
• Sample date: 2026-05-04 08:32 AM
• Ordering provider: Bijay Prabhakaran Nair

Lab Results Extracted

Complete Blood Count:
- Hemoglobin: 11.9 g/dL (L) — improved from 11.4 (Apr 27)
- WBC: 4000 cells/cumm (N) — recovered to normal from 3000 (Apr 27)
- Platelets: 213 K/cumm (N) — stable normal, from 196K (Apr 27)
- RBC: 3.79 million/cumm (L) — improved from 3.66, closest to normal since AML diagnosis
- ANC: 2360 cells/cumm (N) — recovered to normal from 1990 (Apr 27)
- MCV: 95.8 fL (H) — persistent macrocytosis
- RDW: 18.3% (H) — persistent anisocytosis, slight improvement from 18.6
- Hematocrit: 36.3% (N — borderline)
- MCH: 31.4 pg (N)
- MCHC: 32.8 g/dL (N)
- MPV: 9.8 fL (N)

Differential (flow cytometry):
- Polymorphs: 59.0% (calculated 59.8% in report) — normal range
- Lymphocytes: 25.3% (N)
- Monocytes: 7.8% (N)
- Eosinophils: 5.3% (N)
- Basophils: 1.8% (H — slightly elevated)
- Absolute Lymphocyte Count: 1000 cells/cumm (N)
- Absolute Monocyte Count: 310 cells/cumm (N)
- Absolute Eosinophil Count: 210 cells/cumm (N)
- Absolute Basophil Count: 70 cells/cumm (N)

Electrolyte Panel:
- Sodium: 142 mmol/L (N) — normalized from 134 (Apr 27), first normal since Jan 2026
- Potassium: 4.0 mmol/L (N) — stable normal
- Chloride: 103 mmol/L (N) — normalized from 95 (Apr 27)
- Bicarbonate: 24 mmol/L (N) — stable mid-range normal

Magnesium:
- Magnesium: 1.6 mg/dL (N) — normalized from 1.4 (Apr 27), at lower limit of normal

Pages Updated

Lab marker pages (new data point added to longitudinal tables):
- Hemoglobin — 11.9 g/dL (approaching normal)
- Wbc — 4000 cells/cumm (recovered to normal)
- Platelet Count — 213 K/cumm (stable normal)
- Anc — 2360 cells/cumm (recovered to normal)
- Rbc Count — 3.79 million/cumm (closest to normal since AML)
- Sodium — 142 mmol/L (normalized)
- Magnesium — 1.6 mg/dL (normalized)
- Potassium — 4.0 mmol/L (stable normal)
- Chloride — 103 mmol/L (normalized)
- Bicarbonate — 24 mmol/L (stable normal)
- Mcv — 95.8 fL (persistent macrocytosis)
- Rdw — 18.3% (persistent anisocytosis, slight improvement)

Clinical Significance

Multi-lineage hematopoietic recovery: All three cell lines recovering simultaneously after late-April cyclical nadir:
- WBC recovered from leukopenia (3000) to normal (4000)
- ANC recovered from mild neutropenia (1990) to normal (2360)
- Platelets continued stable in normal range (196K → 213K)
- Hemoglobin approaching normal (11.9, only 0.1 g/dL below 12.0 threshold)
- RBC 3.79, only 0.01 million/cumm below normal threshold

Complete electrolyte panel normalization: All previously abnormal electrolytes normalized:
- Sodium: 128 (Apr 20 nadir) → 134 (Apr 27) → 142 (May 4, normal) — first normal since Jan 2026
- Chloride: 93 (Apr 20) → 95 (Apr 27) → 103 (May 4, normal)
- Magnesium: 1.2 (Apr 20 nadir) → 1.4 (Apr 27) → 1.6 (May 4, normal)

Infection risk resolved: ANC normalized to 2360 from 1990. No G-CSF support (pegfilgrastim discontinued Mar 30). Endogenous recovery.

Cross-References

• See Aml, Pancytopenia, Anemia, Hyponatremia (resolved)

Source Count

51 raw sources ingested (49 prior + 1 new: 2026-05-04_Ishamma_T_M.pdf)

2026-05-04 — INGEST: Handwritten Prescription (CRITICAL MEDICATION RECONCILIATION GAP)

• Source: raw/assets/2026-05-04_2026-05-04_172206.jpg
• Document type: Handwritten prescription/medication list
• Date: 2026-05-04
• Patient: Ishamma T M, ID 4096

Critical Discovery

MAJOR MEDICATION RECONCILIATION FAILURE IDENTIFIED.

This handwritten prescription revealed 11 medications, of which 9 were NEVER previously documented in any ingested raw source (no prescription PDFs, no clinic notes mentioning diabetes or cardiovascular medications). This represents a critical gap in the medical record.

Medications Extracted

Previously Undocumented (9):
1. Insulin Degludec (Tresiba) — 10 units SC daily (basal insulin for diabetes)
2. Insulin Glargine (Glin) — 10 units SC daily (evening) — DUAL basal insulin regimen, unusual
3. Linagliptin (Tradjenta) — 5 mg PO daily (DPP-4 inhibitor for diabetes)
4. Metformin (Glulucamio) — 500 mg PO TID (1500 mg/day total, for diabetes)
5. Losartan (Lo) — 50 mg PO daily (ARB for hypertension / diabetic nephropathy)
6. Nifedipine — 30 mg PO BID (60 mg/day, CCB for hypertension)
7. Atorvastatin (Evitof) — dose unknown, PO daily (statin for dyslipidemia)
8. Pregabalin (Pregaserve) — 75 mg PO daily (for neuropathic pain, presumed diabetic neuropathy — NO symptoms documented)
9. Cholecalciferol (Dase) — 2000 IU PO daily (vitamin D3)
10. Serratiopeptidase (Macozac) — 100 mg PO (anti-inflammatory, indication unclear)
11. Prednisolone (Predniod) — dose unknown, PO BID × 15 days (short steroid course, indication unknown)

Previously Documented (0):
- None. Renerve was previously documented but not on this Rx.

Critical Safety Concerns Identified

1. Posaconazole-Atorvastatin Interaction (CYP3A4):
2. Atorvastatin levels increased 3–5 fold by posaconazole
3. HIGH RISK: Rhabdomyolysis (life-threatening muscle breakdown)

4. Consider switching to pravastatin/rosuvastatin (non-CYP3A4 statins)

5. Posaconazole-Nifedipine Interaction (CYP3A4):

6. Nifedipine levels increased 2–3 fold by posaconazole

7. Risk: Excessive hypotension, peripheral edema, headache, dizziness, falls

8. Dual Basal Insulin Regimen:

9. Both Tresiba (degludec) AND Glin (glargine) prescribed — unusual
10. Standard practice: ONE basal insulin

11. Clarification needed: transition period? Split-dose? Documentation error?

12. Prednisolone in Diabetes:

13. Short 15-day steroid course (indication unknown)
14. WORSENS glucose control — causes hyperglycemia, insulin resistance
15. Fructosamine already HIGH (310, Apr 22) — steroids will worsen this

16. Insulin doses will need to be increased during steroid course

17. Prednisolone in AML:

18. Immunosuppression during neutropenic chemotherapy periods

19. Infection risk — patient is on myelosuppressive Aza-Ven

20. Pregabalin Fall Risk:

21. Age 81: high fall risk (dizziness, ataxia, somnolence side effects)
22. 75 mg daily is subtherapeutic for diabetic neuropathy (standard: 150–600 mg/day)

23. NO neuropathic pain symptoms documented in any source

24. Polypharmacy:

25. 16 total active medications (including this Rx + AML meds)
26. Age 81: fall risk, drug interactions, adherence challenges

Monitoring Gaps Identified

1. No blood pressure readings documented — on 2 antihypertensives (losartan, nifedipine)
2. No home glucose monitoring documented — on complex insulin regimen
3. No vitamin D level documented — on 2000 IU daily supplementation
4. No microalbuminuria/UACR documented — losartan for presumed diabetic nephropathy
5. No neuropathic pain assessment documented — on pregabalin for presumed diabetic neuropathy
6. No peripheral edema assessment documented — nifedipine causes edema (10–30%), pregabalin causes edema (6–16%)

Pages Created

Medication pages (11):
- Insulin Degludec
- Insulin Glargine
- Linagliptin
- Metformin
- Losartan
- Nifedipine
- Atorvastatin
- Pregabalin
- Cholecalciferol
- Serratiopeptidase
- Prednisolone

Condition page (1):
- Hypertension — PRESUMED based on medications; NO BP readings documented

Pages Updated

• Active Medications — Complete medication reconciliation update, safety warnings added
• Diabetes Mellitus — 4 medications added to frontmatter, medication section rewritten
• Index — Medication section reorganized by category (16 total active), hypertension added to active conditions
• Log — This entry

Cross-References Maintained

• Medications ↔ Diabetes Mellitus
• Medications ↔ Hypertension (new)
• Medications ↔ Aml (drug interactions with posaconazole)
• Medications ↔ lab markers (potassium, creatinine, lipid panel, fructosamine)

Clinical Significance

This ingest revealed a catastrophic documentation gap. Nine medications — including insulin, oral diabetes drugs, and cardiovascular medications — were being administered with zero documentation in the medical record available to the wiki. This has profound implications:

1. Medication reconciliation was incomplete — AML team may not be aware of all medications
2. Drug interactions were undetected — posaconazole-atorvastatin and posaconazole-nifedipine interactions are HIGH-RISK
3. Glycemic control assessment was incomplete — fructosamine 310 (HIGH) despite 4-drug diabetes regimen suggests inadequate dosing or poor adherence
4. Fall risk was underestimated — 16 medications in age 81 patient, including pregabalin (CNS depressant)
5. Indication gaps — prednisolone and pregabalin prescribed without documented clinical indication

Recommendations:
1. Obtain all prescription records and add to raw/prescriptions/
2. Perform comprehensive medication reconciliation with all providers
3. Assess posaconazole-atorvastatin interaction: consider switching atorvastatin to pravastatin/rosuvastatin
4. Monitor nifedipine levels/effects during posaconazole co-administration
5. Clarify dual basal insulin regimen (degludec vs. glargine)
6. Obtain baseline monitoring: BP readings, home glucose log, vitamin D level, microalbuminuria, neuropathy assessment
7. Assess indication for prednisolone (15-day course) and pregabalin (no documented neuropathy symptoms)

2026-05-06 — QUERY: Duloxetine vs. Mirtazapine for Diabetic Neuropathy

• Query: "For her, is Cymbalta or mirtazapine better for diabetic neuropathy?"
• Wiki pages consulted: wiki/medications/pregabalin.md, wiki/conditions/diabetes-mellitus.md, wiki/profile.md, wiki/hot.md, wiki/index.md
• Synthesis filed: wiki/syntheses/duloxetine-vs-mirtazapine-diabetic-neuropathy.md
• Conclusion: Duloxetine preferred — FDA-approved first-line for DPN, no CYP3A4 interaction with posaconazole (unlike mirtazapine). Key caveat: prior SIADH — monitor Na if started.
• Gaps flagged: GFR, LFTs, formal DPN diagnosis documentation, pain NRS score, Na recheck before SNRI start

2026-05-06 — QUERY: Duloxetine (Cymbalta) optimal dosing time

• Query: "Cymbalta what time to take"
• Answer: Morning with food (q.d.); full rationale logged in response. No synthesis filed — straightforward pharmacokinetic/tolerability query. No new wiki gaps identified beyond those already documented in Duloxetine Vs Mirtazapine Diabetic Neuropathy.

2026-05-06 — QUERY: Grapefruit / fruit juice dietary restrictions

• Query: "Is there a grape juice or fruit restriction for her based on meds"
• Answer: Yes — strict grapefruit/Seville orange/pomelo restriction due to CYP3A4 interactions with venetoclax, atorvastatin, and nifedipine. GFJ effect is additive on already posaconazole-saturated CYP3A4. Regular grape juice (Vitis vinifera) is safe — no furanocoumarin content.
• Filed: Grapefruit Fruit Juice Restrictions
• Pages read: Venetoclax, Atorvastatin, Nifedipine, Posaconazole, Losartan, Metformin
• Gaps noted: None new (existing CYP3A4 posaconazole interactions already documented)

2026-05-06 — INGEST: Clinic note 20260506_151247_note.md

• Source: raw/clinic-notes/20260506_151247_note.md
• Document type: Clinic note (single-line)
• Content: "she is not taking nifedipine"
• Key finding: Patient non-adherence to nifedipine confirmed. Nifedipine was documented as active on the 2026-05-04 prescription but has not been taken by the patient.
• Pages updated:
• Nifedipine — status changed active → discontinued (non-adherence, confirmed 2026-05-06); dosing history table updated; non-adherence callout added
• Active Medications — nifedipine moved from Cardiovascular (active) to Discontinued table; posaconazole-nifedipine interaction flagged as RESOLVED; active count updated 16 → 15; cardiovascular category reduced from 3 to 2 medications
• Hypertension — frontmatter medications list updated (nifedipine removed); clinical summary updated; combination therapy section revised to monotherapy; monitoring gaps table updated; drug interactions section updated to reflect interaction now moot; footnote updated
• Grapefruit Fruit Juice Restrictions — Summary callout updated (3 → 2 active medications with GFJ restriction); nifedipine row in summary table marked NOT CURRENTLY ACTIVE; nifedipine detail section revised with "not taking" notice
• Index — medication count updated 16 → 15; nifedipine added to discontinued section; cardiovascular count updated 3 → 2; raw sources 53 → 54; last ingest date updated
• Contradiction resolved: Nifedipine was listed as active in wiki (source: 2026-05-04 Rx); clinic note establishes it has not been taken. Wiki now reflects most recent clinical truth (not being taken).
• Interaction resolved: Posaconazole-nifedipine CYP3A4 interaction (previously flagged as high-risk) is now clinically moot — nifedipine not being taken.
• New gap flagged: Antihypertensive regimen is now losartan monotherapy only. If hypertension is confirmed, losartan alone may be insufficient. Prescriber notification warranted. BP readings remain undocumented.
• Sources: 53 → 54

2026-05-06 — INGEST: Clinic note 20260506_155027_note.md

• Source: raw/clinic-notes/20260506_155027_note.md
• Document type: Clinic note (single-line)
• Content: "she is taking Magnesium (oral supplement) 400mg tid"
• Key findings:
• Dose documented for first time: 400 mg TID (three times daily) = 1200 mg/day total. This is the maximum recommended oral magnesium dose per Magnesium Glycinate Oral Dosing.
• Status corrected: Magnesium oral supplement was listed as discontinued (supply lapsed ~2026-04-06). This clinic note confirms it has been resumed and is actively being taken.
• Clinical correlation: Mg normalized to 1.6 mg/dL (May 4) — the first normal value since AML treatment began. The 400 mg TID regimen is responsible for this normalization.
• Pages updated:
• Magnesium Oral — status changed discontinued → active; dose updated from "Unknown" to 400 mg TID; dose history table added; clinical correlation with Mg normalization documented; source reference added
• Active Medications — magnesium-oral moved from Discontinued table back to active Supplements section; dose 400 mg TID documented in table; Clinical Notes callout updated from warning to success; active medication count 12 → 13; Supplements category updated 2 → 3; source reference added; footer updated
• Contradiction resolved: Magnesium-oral was listed as discontinued in the wiki; this note establishes the patient is actively taking it. Wiki updated to reflect current clinical truth.
• Gap partially resolved: Magnesium dose was previously unknown. Now documented as 400 mg TID. Formulation and prescriber remain unknown.
• Sources: 55 → 56

2026-05-06 — INGEST: Clinic note 20260506_154920_note.md

• Source: raw/clinic-notes/20260506_154920_note.md
• Document type: Clinic note (single-line)
• Content: "she is not taking Insulin Glargine (Glin)"
• Key finding: Patient non-adherence to insulin glargine confirmed. Insulin glargine was documented on the 2026-05-04 handwritten prescription (10 units SC, 0-0-1) but has not been taken by the patient.
• Pages updated:
• Insulin Glargine — status changed active → discontinued (non-adherence, confirmed 2026-05-06); date_discontinued set to 2026-05-06; "NOT BEING TAKEN" callout added; dosing history table updated with non-adherence row; dual basal insulin question resolved (RESOLVED callout added); source reference added
• Active Medications — insulin glargine removed from Diabetes Medications table; moved to Discontinued section; dual basal insulin warning replaced with RESOLVED callout; active count updated 14 → 13; Diabetes category reduced 4 → 3; adherence pattern note updated (3 → 4 non-adherent meds)
• Diabetes Mellitus — insulin glargine removed from frontmatter medications array; removed from Current Diabetes Regimen numbered list; item numbering corrected; 2022 historical footnote updated; dual insulin concern resolved in callout; glycemic control assessment revised; sources updated
• Index — insulin glargine moved to discontinued section; diabetes medication count 4 → 3; total active medication count reflects ongoing updates
• Contradiction resolved: Insulin glargine was listed as active in wiki (source: 2026-05-04 Rx); clinic note establishes it is not being taken. Wiki reflects current clinical truth.
• Dual basal insulin question RESOLVED: The previously flagged clinical concern about concurrent Tresiba + Glin is explained by non-adherence — patient only takes Tresiba (degludec). No unusual pharmacology involved; the dual-insulin appearance was a prescription documentation artifact.
• Sources: 56 → 57

Activity Log

2026-05-06 — INGEST: Clinic note 20260506_154959_note.md

• Source: raw/clinic-notes/20260506_154959_note.md
• Document type: Clinic note (single-line)
• Content: "she is not taking Prednisolone (Predniod)"
• Key finding: Patient non-adherence to prednisolone confirmed. Prednisolone was documented as active on the 2026-05-04 handwritten prescription (15-day course, 1-0-1) but has not been taken by the patient.
• Pages updated:
• Prednisolone — status changed active → discontinued (non-adherence, confirmed 2026-05-06); date_discontinued set to 2026-05-06; reason updated; source reference added; "NOT BEING TAKEN" callout added to clinical summary
• Active Medications — prednisolone removed from active "Short-Course Steroids" section; moved to Discontinued table; danger callout items 4 & 5 (prednisolone-diabetes and prednisolone-AML risks) struck through as RESOLVED; active count updated 13 → 12; polypharmacy alert updated; source reference added
• Index — medication count updated 13 → 12; prednisolone moved from active list to discontinued; danger callout updated; raw sources count updated 57 → 58
• Contradiction resolved: Prednisolone was listed as active in wiki (source: 2026-05-04 Rx); clinic note establishes it has not been taken. Wiki now reflects most recent clinical truth (not being taken).
• Clinical implications: Steroid-related risks now resolved — hyperglycemia worsening and infection risk augmentation no longer active. Current diabetes control (fructosamine 310, poor) is not being further confounded by prednisolone. This is clinically favorable.
• Adherence pattern note: This is the 4th medication confirmed not being taken despite written prescription (nifedipine, atorvastatin, insulin glargine, prednisolone). Significant prescriber-patient adherence gap warrants attention.

2026-05-06 — LINT: /lint command

• Trigger: /lint
• Scope: Full wiki (~127 pages)
• Auto-fixes applied (3):
• wiki/conditions/pancytopenia.md — status: active → resolved; date_resolved: 2026-05-04 added; body updated with resolution callout
• wiki/conditions/hyponatremia.md — status: active → resolved; date_resolved: 2026-05-04 added; May 4 data row (Na 142, Cl 103) appended
• wiki/imaging/_imaging-timeline.md — populated with 3 existing studies (ABI Doppler, Biothesiometry, Monofilament — 2022-11-25)
• Flags raised: 15 (5 clinical, 6 documentation, 4 structural) — see Lint Report 2026 05 06
• Critical clinical flags: BP undocumented (on antihypertensive), falls risk assessment absent, fructosamine recheck due ~May 20, Cr/renal function due, prednisolone indication never documented
• Broken wikilinks: 0
• Missing directories: 0
• Report filed: Lint Report 2026 05 06

2026-05-06 — QUERY: /lint writeback

• Trigger: Post-lint writeback
• Synthesis filed: Lint Report 2026 05 06 (wiki/syntheses/)
• Log entry already present from the lint run itself (see below)
• hot.md updated: New gaps from lint added to ## Gaps section

2026-05-06 — QUERY: overview update

• Trigger: User requested update of wiki/overview.md
• Pages updated: Overview
• Changes: Full rewrite to reflect May 4–6 data. Resolved conditions added (pancytopenia, hyponatremia). May 4 multi-lineage recovery reflected (WBC 4000 N, ANC 2360 N, Plt 213K N, Hb 11.9). Electrolyte normalization reflected (Na 142 N, Mg 1.6 N, Cl 103 N). Active medication table updated (13 active; 4 confirmed non-adherent). Concerns section restructured with 11 active items. Frontmatter updated: corrected to 2026-05-06. Gap noted: wiki/overview.md updated: stale from lint report — RESOLVED.

2026-05-11 — INGEST: Lab report (CBC + Electrolytes + Magnesium)

• Source: raw/labs/2026-05-11_Ishamma_T_M_A.pdf
• Document type: Lab report — Complete Blood Count + Electrolyte Panel + Magnesium
• Facility: KIMS Health Laboratory Medicine
• Ordering provider: Dr. Bijay Prabhakaran Nair
• Bill No: L035372426
• Sample collected: 2026-05-11 08:07 AM
• Pages updated (15 lab marker pages):
• Hemoglobin — 11.8 g/dL (L, stable −0.1 from May 4)
• Wbc — 5700 cells/cumm (N, +1700 from May 4)
• Anc — 3950 cells/cumm (N, +1590 from May 4)
• Platelet Count — 113K (L, −100K from May 4) — NEW THROMBOCYTOPENIA (47% drop)
• Rbc Count — 3.73 million/cumm (L, −0.06 from May 4)
• Mcv — 96.8 fL (H, +1.0 from May 4, persistent macrocytosis)
• Rdw — 18.2% (H, stable from May 4, persistent anisocytosis)
• Sodium — 137 mmol/L (N, −5 from May 4, stable normal)
• Potassium — 4.5 mmol/L (N, stable)
• Chloride — 96 mmol/L (L, −7 from May 4) — RE-DROPPED below normal
• Bicarbonate — 29.1 mmol/L (H borderline, +5.1 from May 4, at upper limit 29)
• Magnesium — 1.5 mg/dL (L, −0.1 from May 4) — RE-DROPPED below normal
• Timeline updated: Lab Timeline — May 11 entry added
• Index updated: Index — 59 → 60 sources, last updated 2026-05-11
• Key clinical findings:
• NEW THROMBOCYTOPENIA: Platelet count dropped sharply from 213K → 113K (−100K, 47% decline) over 7 days. Bleeding risk now elevated. Consistent with cyclical Aza-Ven myelosuppression.
• Dissociated lineage kinetics: WBC/ANC remain elevated and normal (5700, 3950) while platelets dropped sharply. Classic pattern: platelet nadir precedes neutrophil nadir by 3-7 days. WBC/ANC drop expected ~May 15-20.
• ELECTROLYTE DISTURBANCE RECURRING: The brief May 4 normalization was NOT sustained:
  • Mg: 1.6 (N) → 1.5 (L) — re-dropped below normal
  • Cl: 103 (N) → 96 (L) — re-dropped below normal
  • HCO3: 24.0 (N) → 29.1 (H borderline) — rose to upper limit
  • Na remains normal (137 mmol/L), K remains normal (4.5 mmol/L)
• Inadequate Mg supplementation: Current regimen (400 mg TID = 1200 mg/day per May 6 clinic note) is insufficient to achieve sustained normalization. Consider dose escalation or IV repletion.
• Cross-references: Dr. Bijay Prabhakaran Nair (ordering provider, already has wiki page)
• Source count: 59 → 60

2026-05-13 — SESSION START

• Query: Session greeting ("Hi")
• Action: Session initialized. Hot cache and index read. No ingest or synthesis performed.
• Summary: Patient: Ishamma T M, 81F, AML (Aza-Ven). Last data point 2026-05-11 labs noted (Plt 113K, Mg 1.5, Cl 96).

2026-05-17 — QUERY: "Will transfer" (incomplete)

• Query: "Will transfer" — incomplete sentence, meaning indeterminate
• Action: Clarification requested. No wiki pages read beyond hot cache. No synthesis filed.
• Possible interpretations surfaced: care transfer, transfusion, port transfer, venetoclax transfer, technology transfer.
• Outcome: Awaiting user clarification to complete query.

2026-05-17 — INGEST: Lab report (CBC + Electrolyte Panel)

• Source: raw/labs/2026-05-17_Ishamma_T_M_1.pdf
• Document type: Lab report — Complete Blood Count (CBC) + Electrolyte Panel
• Facility: KIMS Health Laboratory Medicine
• Ordering provider: Dr. Bijay Prabhakaran Nair
• Bill No: L037179526
• Sample collected: 2026-05-17 07:42 AM
• Sample received: Blood 09:11 AM, Serum 08:08 AM
• Pages updated (11 lab marker pages):
• Hemoglobin — 9.9 g/dL (L, SEVERE DROP −1.9 from May 11 in 6 days, sharpest decline since Nov 2025, back to mid-March levels)
• Wbc — 4600 cells/cumm (N, −1100 from May 11, trending down, nadir imminent)
• Platelet Count — 103 K (L, continued thrombocytopenia −10K from May 11, below 100K bleeding risk threshold)
• Anc — 3400 cells/cumm (N, −550 from May 11, trending down, nadir expected May 20-24)
• Rbc Count — 3.17 million/cumm (L, SEVERE DROP −0.56 from May 11, 15% decline)
• Sodium — 140 mmol/L (N, +3 from May 11, continued normal)
• Potassium — 4.7 mmol/L (N, stable)
• Chloride — 103 mmol/L (N, RE-NORMALIZED from 96, all electrolytes now normal)
• Bicarbonate — 25.7 mmol/L (N, NORMALIZED from 29.1)
• Mcv — 94.6 fL (H, persistent macrocytosis, −2.2 from May 11)
• Rdw — 17.8% (H, persistent anisocytosis, slight improvement)
• Cross-references updated: Aml, Anemia, Pancytopenia, Hyponatremia
• Clinical significance:
• SEVERE HEMATOLOGIC DETERIORATION: This lab demonstrates profound cyclical Aza-Ven myelosuppression affecting red cell and platelet lineages simultaneously. Hemoglobin dropped 1.9 g/dL in 6 days (11.8 → 9.9), the sharpest decline since pre-diagnosis/early treatment November 2025. RBC count dropped 15% (3.73 → 3.17 M). Patient has lost all hemoglobin/RBC gains from the past 2 months.
• LINEAGE CASCADE CONFIRMED: Classic dissociated kinetics: platelet nadir May 11 (113K), Hb/RBC nadir May 17 (9.9/3.17M), WBC/ANC nadir expected May 20-24. Infection risk will rise significantly when ANC drops below 1500.
• BLEEDING RISK ELEVATED: Platelets at 103K, below the 100K procedural/trauma safety threshold (spontaneous bleeding risk <50K). Avoid invasive procedures, IM injections, NSAIDs, anticoagulants.
• ELECTROLYTE NORMALIZATION: All electrolytes normalized (Na 140, Cl 103, HCO3 25.7) — the May 11 disturbances (Cl 96 low, HCO3 29.1 borderline high) have resolved.
• ANEMIA APPROACHING SYMPTOMATIC: At 9.9 g/dL, patient is approaching symptomatic anemia threshold (fatigue, dyspnea, dizziness). Transfusion threshold typically 7-8 g/dL in stable patients.
• Index updated: Source count 60 → 61, summary updated with May 17 severe deterioration
• Timestamp: 2026-05-17

2026-05-24 — QUERY: Medication list

• Query: "Medication list"
• Pages read: Hot, Index, Active Medications
• Answer: Full active medication table retrieved (13 medications: 5 AML/supportive, 3 DM, 1 CV, 1 neuropathic pain, 3 supplements). 4 confirmed non-adherent (nifedipine, atorvastatin, insulin glargine, prednisolone) moved to discontinued.
• Synthesis filed: No — straightforward retrieval from Active Medications
• Gaps noted: Oncology drug doses unknown; adherence beyond the 4 documented non-adherent medications unconfirmed; serratiopeptidase indication unclear

2026-05-27 — QUERY: Travel clearance assessment

• Query: "Based on current is it ok to travel"
• Pages read: Hot, Index, Aml, Hemoglobin, Anc, Platelet Count
• Answer: NOT travel-suitable. Active myelosuppressive nadir (Hb 9.9, Plt 103K, ANC nadir projected May 20–24), febrile neutropenia risk without G-CSF backup, symptomatic anemia risk (81F + pregabalin + Hb 9.9), active thrombocytopenia (Plt 103K), and poor DM control (fructosamine 310). Travel requires post-nadir CBC confirmation, Dr. Bijay clearance, and pre-identified hospital at destination.
• Synthesis filed: Travel Clearance 2026 05 27
• Gaps noted: Cycle 5 exact start date unknown; no May 2026 clinic note; BP never measured

2026-05-27 — INGEST: 3 PDF files (2 unique lab reports — May 23 and May 27)

• Sources ingested:
• raw/labs/20260527_Ishamma T M 1 5-27-2.pdf — Bill L040020926, 2026-05-27 CBC + Electrolytes (unique)
• raw/labs/20260527_Ishamma T M 5-27-1.pdf — Bill L038904126, 2026-05-23 CBC + Electrolytes (unique)
• raw/labs/20260527_Ishamma T M 5-27.pdf — Bill L038904126, 2026-05-23 (exact duplicate of 5-27-1 — source reference added, data not re-ingested)
• Facility: KIMS Health Laboratory Medicine | Ordering provider: Dr. Bijay Prabhakaran Nair
• Document type: CBC + Electrolyte Panel (both dates)

2026-05-23 results (Bill L038904126):
- Hb 11.6 (L), WBC 3500 (L), ANC 2430 (N borderline), Plt 117 (L), RBC 3.76 (L), MCV 94.7 (H), RDW 18.0 (H). Smear checked.
- Na 141 (N), K 4.6 (N), Cl 99 (N), HCO3 29.5 (H — borderline above limit 29)

2026-05-27 results (Bill L040020926):
- Hb 12.0 (N — FIRST NORMAL Hb since AML diagnosis), WBC 2400 (L), ANC 1460 (L — moderate neutropenia, NADIR), Plt 107 (L), RBC 3.77 (L), MCV 95 (H), RDW 17.8 (H)
- Na 137 (N), K 4.4 (N), Cl 98 (N, lower limit), HCO3 28 (N)

Clinical significance:
- Landmark: Hb 12.0 is the first hemoglobin in the normal reference range (12–15 g/dL) since AML diagnosis in November 2025 — ~7 months of treatment
- Lineage cascade confirmed: Plt nadir May 11 (103K) → Hb nadir May 17 (9.9) → WBC/ANC nadir May 27 (2400/1460) — classic Aza-Ven dissociated lineage kinetics, on predicted schedule
- ANC 1460 = moderate neutropenia (below 1500 threshold). Infection risk elevated. Acyclovir + posaconazole prophylaxis critical
- Bicarbonate mildly elevated May 23 (29.5) but normalized May 27 (28) — no clinical significance
- No Magnesium on these panels (last 1.5 on May 11 — still below normal)

Pages updated (no new pages created):
- Hemoglobin — 2 new data points; trend narrative updated (landmark first normal noted)
- Wbc — 2 new data points; nadir warning added
- Anc — 2 new data points; nadir warning updated
- Platelet Count — 2 new data points; stabilization pattern noted
- Rbc Count — 2 new data points; recovery noted
- Mcv — 2 new data points
- Rdw — 2 new data points
- Sodium — 2 new data points
- Potassium — 2 new data points
- Chloride — 2 new data points
- Bicarbonate — 2 new data points (May 23 borderline H, May 27 N)
- Lab Timeline — 3 new entries (May 17 was missing, now added; May 23 and May 27 added)
- Lab Trends — Key markers table updated to May 27 values; summary updated
- Index — Updated counts, current values, source count 61→63
- Overview + Profile — to be updated (next step)
- Source count: 61 → 63

2026-05-27 — QUERY: "Based on current is it ok to travel" (2nd pass — nadir now confirmed)

• Query: Travel clearance assessment re-run after May 27 labs confirmed.
• Answer: NOT travel-suitable. ANC nadir confirmed: WBC 2400 (L), ANC 1460 (L — moderate neutropenia). Hb 12.0 (N — landmark, first normal since AML Dx) — Hb normalization does NOT resolve the neutropenia contraindication. Plt 107K (L, thrombocytopenic, stabilizing).
• Earliest plausible window: ~June 4–10, 2026 if serial CBC confirms ANC recovery ≥1500–2000. Requires Dr. Bijay explicit clearance + fresh labs within 48–72h of departure.
• Synthesis updated: Travel Clearance 2026 05 27 — confirmed nadir table added, timing updated.

2026-05-27 — WRITEBACK: Travel query writeback (3rd pass — synthesis corrections + gap update)

• Action: Post-query writeback pass.
• Synthesis Travel Clearance 2026 05 27 corrected: Stale "Hb 9.9" anemia contraindication replaced with accurate "Hb 12.0 N" note; Plt reference updated to May 27 value (107K); anemia section reframed to orthostatic/fall risk (Hb no longer a contraindication).
• hot.md updated: Last Query entry updated to reflect confirmed nadir. New gap added: No May 2026 clinic note from Dr. Bijay.
• New gaps documented: May 2026 clinic note absence; BP unmeasured (pre-existing, reinforced).

2026-05-29 — INGEST: Duplicate lab report (May 27 CBC + Electrolytes)

• Source ingested: raw/labs/2026-05-29_Ishamma_T_M_1.pdf — Bill L040020926, 2026-05-27 CBC + Electrolytes
• Document type: Lab report — Complete Blood Count (CBC) + Electrolyte Panel
• Facility: KIMS Health Laboratory Medicine | Ordering provider: Dr. Bijay Prabhakaran Nair
• Status: DUPLICATE — Exact duplicate of previously ingested raw/labs/20260527_Ishamma T M 1 5-27-2.pdf (same bill number L040020926, same date, same values)
• Action: Source reference added to existing lab marker pages. No data re-extraction. No new pages created.
• Data: Hb 12.0 (N — landmark first normal), WBC 2400 (L), ANC 1460 (L — moderate neutropenia nadir), Plt 107 (L), Na 137 (N), K 4.4 (N), Cl 98 (N), HCO3 28 (N)
• Pages updated: Source reference added to 11 lab marker pages (Hemoglobin, Wbc, Anc, Platelet Count, Rbc Count, Mcv, Rdw, Sodium, Potassium, Chloride, Bicarbonate)
• Source count: 63 → 64

2026-05-29 — INGEST: Duplicate lab report (May 23 CBC + Electrolytes) — raw/labs/

• Source ingested: raw/labs/2026-05-29_Ishamma_T_M.pdf — Bill L038904126, 2026-05-23 CBC + Electrolytes
• Document type: Lab report — Complete Blood Count (CBC) + Electrolyte Panel
• Facility: KIMS Health Laboratory Medicine | Ordering provider: Dr. Bijay Prabhakaran Nair
• Status: DUPLICATE — Exact duplicate of previously ingested raw/labs/20260527_Ishamma T M 5-27-1.pdf (same bill number L038904126, same date, same values)
• Action: Source reference added to existing lab marker pages. No data re-extraction. No new pages created.
• Data: Hb 11.6 (L), WBC 3500 (L), ANC 2430 (N borderline), Plt 117 (L), RBC 3.76 (L), MCV 94.7 (H), RDW 18.0 (H). Na 141 (N), K 4.6 (N), Cl 99 (N), HCO3 29.5 (H borderline)
• Pages updated: Source reference added to 11 lab marker pages (Hemoglobin, Wbc, Anc, Platelet Count, Rbc Count, Mcv, Rdw, Sodium, Potassium, Chloride, Bicarbonate)
• Source count: 64 → 65

2026-05-29 — FILE ORGANIZATION: raw/assets/ → raw/labs/

• File moved: raw/assets/2026-05-29_Ishamma_T_M.pdf → raw/labs/2026-05-29_Ishamma_T_M.pdf
• Classification: Lab report (CBC + Electrolytes, Bill L038904126, May 23 2026)
• Wiki pages updated: 13 pages (11 lab marker pages + index.md + log.md)
• Source references rewritten: All <a href="/raw/assets/2026-05-29_Ishamma_T_M.pdf" class="wikilink">Raw/Assets/2026 05 29 Ishamma T M.Pdf</a> → <a href="/raw/labs/2026-05-29_Ishamma_T_M.pdf" class="wikilink">Raw/Labs/2026 05 29 Ishamma T M.Pdf</a>
• Action: File organization pass — raw sources reorganized into correct subfolders based on document type

2026-06-01 — INGEST: CRITICAL June 1 CBC — SEVERE NEUTROPENIA

• Source ingested: raw/labs/2026-06-01_Ishamma_T_M.pdf — Bill L041256126, 2026-06-01 CBC (no electrolytes)
• Document type: Lab report — Complete Blood Count (CBC) only
• Facility: KIMS Health Laboratory Medicine | Ordering provider: Dr. Bijay Prabhakaran Nair | Pathologist: Dr. Padmini R
• Sample collected: 2026-06-01 11:11 AM | Authorized: 2026-06-01 12:27 PM (CBC), 02:19 PM (Hct)
• Status: CRITICAL CLINICAL FINDING — SEVERE NEUTROPENIA (Grade 3)

Key Findings:

• ANC 990 cells/cumm (L) — SEVERE NEUTROPENIA (CTCAE Grade 3, <1000 threshold). Deepest ANC nadir since March 2026 stabilization. Approaching February 2026 crisis levels (610-880). CRITICALLY ELEVATED infection risk.
• WBC 2200 cells/cumm (L) — Deepest leukopenia nadir since stabilization. −200 from May 27 (2400).
• Platelet count 252 K (N) — FULLY RECOVERED to normal range (+145K from May 27). Bleeding risk resolved. Confirms lineage dissociation: platelets recovered ~10 days before granulocytes.
• Hemoglobin 11.3 g/dL (L) — Dropped −0.7 from May 27 landmark normal (12.0). Returned to anemic range. Possible hemodilution or erythroid suppression lagging recovery.
• MCV 100 fL (H) — HIGHEST KIMS MCV ON RECORD. Worsening macrocytosis (+5.0 from May 27). Exceeds prior DDRC peak (99.8).
• RBC 3.53 million/cumm (L) — Secondary drop −0.24 from May 27 (3.77).
• Differential: Polymorphs 46% (lowest on record), Lymphs 42.8% (relative lymphocytosis), Monos 5.6%, Eos 3.7%, Baso 1.9% (H).
• Absolute counts: ALC 920 (L), AMC 120 (L), AEC 80 (L), ABC 40 (L).
• Red cell indices: Hct 35.3% (L), MCH 32 (N), MCHC 32 (N), RDW 18.3% (H — persistent anisocytosis).
• MPV: 11.1 fL (upper normal).

Clinical Context:

SEVERE NEUTROPENIA NADIR — CRITICAL INFECTION RISK PERIOD

May-June 2026 lineage cascade (extended):
- Platelet nadir: May 11-17 (103-113K)
- Hemoglobin/RBC nadir: May 17 (9.9 g/dL, 3.17 M/cumm)
- WBC/ANC nadir: May 27 - June 1 (WBC 2400→2200, ANC 1460→990)

Dissociated lineage kinetics confirmed: Platelets fully recovered to 252K (normal) while ANC at deepest nadir (990). Hemoglobin transiently reached first-ever normal (12.0 on May 27), then dropped to 11.3 (June 1). MCV escalation to 100 fL signals worsening macrocytosis (azacitidine cumulative effect + stress erythropoiesis).

Infection risk: CRITICALLY ELEVATED. Life-threatening bacterial/fungal infection risk. Acyclovir + posaconazole prophylaxis ESSENTIAL. Fever >38°C requires urgent evaluation. Monitor for mucositis, skin infections, respiratory symptoms. Avoid crowds, sick contacts, uncooked food.

Expected recovery: Based on platelet recovery trajectory (Plt 252K, fully normal), ANC should begin rising within 3-7 days (~June 4-8). Repeat CBC in 2-3 days to confirm turnaround. No G-CSF available (pegfilgrastim discontinued due to bone pain).

Gap: No electrolytes on June 1 panel. Magnesium status unknown (last 1.5 mg/dL [L] on May 11). Sodium last 137 (N) on May 27.

Pages Updated:

• Lab marker pages (10): Hemoglobin (31 data points), Wbc (32 data points), Anc (30 data points), Platelet Count (31 data points), Rbc Count (30 data points), Mcv (31 data points), Rdw (31 data points)
• Meta pages (4): Lab Timeline, Overview, Hot, Index
• Source count: 65 → 66
• Pages: 99 (no new pages)

2026-06-06 — INGEST: RECOVERY CONFIRMED — June 6 Comprehensive Panel

• Source ingested: raw/labs/2026-06-07_Ishamma_T_M_1.pdf — Bill L042743426, 2026-06-06 comprehensive metabolic panel + CBC + LFT
• Document type: Lab report — Complete Blood Count (CBC), Electrolyte Panel, Creatinine, Hepatic Panel 2 (LFT)
• Facility: KIMS Health Laboratory Medicine | Ordering provider: Dr. Bijay Prabhakaran Nair
• Sample collected: 2026-06-06 10:50 AM (Serum: 10:50 AM, Blood: 10:50 AM) | Authorized: 2026-06-06 11:58 AM (CBC), 12:21-12:26 PM (Chemistry, LFT)
• Status: RECOVERY CONFIRMED — MULTI-LINEAGE HEMATOPOIETIC RECOVERY

Key Findings:

CBC (RECOVERY CONFIRMED):
- ANC 1240 cells/cumm (L — moderate neutropenia) — EXITED SEVERE NEUTROPENIA (+250 from June 1 nadir of 990). Infection risk downgraded from critically elevated to elevated. Grade 3 → Grade 2.
- WBC 2500 cells/cumm (L — leukopenia recovering) — +300 from June 1 nadir (2200). Recovery trajectory initiated.
- Hemoglobin 12.1 g/dL (N — RECOVERED TO NORMAL) — +0.8 from June 1 (11.3). Second sustained normal hemoglobin since AML diagnosis. Anemia RESOLVED.
- Platelet count 241 K (N — stable normal) — −11K from June 1 (252K), stable within normal range. Bleeding risk remains resolved.
- RBC 3.82 million/cumm (N borderline) — +0.29 from June 1 (3.53). Near-normal recovery — only 0.02 million/cumm below lower limit of normal (3.80-4.80).
- MCV 96.3 fL (H — improved) — −3.7 from June 1 peak (100 fL). Macrocytosis decreased. June 1 spike likely transient stress erythropoiesis.
- RDW 17.2% (H — improved) — −1.1 from June 1 (18.3%). Anisocytosis decreased.
- Hematocrit 36.8% (N — normalized) — Within reference range 36-47% (was 35.3% June 1).
- Differential: Polymorphs 49.3% (improved from 46% June 1), Lymphs 35.5% (decreased from 42.8% — relative lymphocytosis resolving), Monos 9.2% (normalized from 5.6%), Eos 3.6%, Baso 2.4% (H, decreased from 2.4% June 1).
- Absolute counts: ALC 890 (L), AMC 230 (N — normalized from 120), AEC 90 (N), ABC 60 (N).
- Red cell indices: MCH 31.7 (N), MCHC 32.9 (N), MPV 10.4 (N).

ELECTROLYTES (ALL NORMAL — STABLE):
- Sodium 139 mmol/L (N) — +2 from May 27 (137). Stable normal.
- Potassium 4.8 mmol/L (N) — +0.4 from May 27 (4.4). Normal.
- Chloride 99 mmol/L (N) — +1 from May 27 (98). Normal.
- Bicarbonate 28.2 mmol/L (N) — +0.2 from May 27 (28.0). Normal.

RENAL FUNCTION (NORMAL — STABLE):
- Creatinine 0.6 mg/dL (N) — Stable at lower limit. Renal function preserved throughout Aza-Ven treatment.

LIVER FUNCTION TESTS (ALL NORMAL — NO HEPATOTOXICITY):
- Bilirubin Total 0.3 mg/dL (N) — Normal (ref <1.2).
- Bilirubin Direct 0.1 mg/dL (N) — Normal (ref 0-0.30).
- ALT 19 U/L (N) — Slightly increased from 11 (April 6) but well within normal range (10-35).
- AST 19 U/L (N) — Slightly increased from 15 (April 6), still normal (10-35).
- ALP 73 U/L (N) — Increased from 63 (April 6), normal (35-104).
- Total Protein 7.2 g/dL (N) — Normal (6.80-8.70).
- Albumin 4.4 g/dL (N) — Stable, normal (3.50-5.20). Good synthetic function.
- Globulin 2.86 g/dL (N) — Calculated, normal (2.20-3.60).

Clinical Context:

NADIR RESOLVED — MULTI-LINEAGE RECOVERY CONFIRMED

The June 1 severe neutropenia nadir (ANC 990, WBC 2200 — deepest since March 2026 stabilization) has resolved. All three hematopoietic lineages are now recovering coordinately:

1. Platelet recovery (complete): May 11-17 nadir (103-113K) → June 1-6 stable normal (241-252K)
2. Erythroid recovery (complete): May 17 nadir (Hb 9.9, RBC 3.17) → June 6 normalized (Hb 12.1, RBC 3.82)
3. Granulocyte recovery (in progress): May 27-June 1 nadir (ANC 1460 → 990) → June 6 improving (ANC 1240)

Recovery trajectory:
- Platelets recovered first (~10-14 days ahead of granulocytes) — classic Aza-Ven lineage dissociation pattern
- Hemoglobin followed platelet recovery by ~5 days, now normalized
- ANC exited severe neutropenia range, expected to continue rising to normal (>2000) within 5-10 days based on prior cycle patterns

Infection risk: Downgraded from critically elevated to elevated. ANC >1000 significantly reduces risk of life-threatening infections. Continue acyclovir and posaconazole prophylaxis. Standard neutropenic precautions remain.

Anemia: RESOLVED. Hemoglobin 12.1 g/dL is within normal range (12-15) — second sustained normal since diagnosis.

Renal and hepatic function: Stable and normal despite continued Aza-Ven + posaconazole therapy. No drug-induced organ toxicity.

Macrocytosis: Improved from June 1 peak (MCV 100 → 96.3 fL). Transient June 1 spike likely stress erythropoiesis during nadir period.

Pages Updated (16 lab marker pages):

• CBC markers (7): Wbc, Anc, Hemoglobin, Rbc Count, Platelet Count, Mcv, Rdw
• Electrolytes (4): Sodium, Potassium, Chloride, Bicarbonate
• Renal (1): Creatinine
• Hepatic (1): Lft
• Master pages (3): Index, Profile, Log

Source Count Update:

• Previous: 66 raw sources
• New: 67 raw sources
• New source: raw/labs/2026-06-07_Ishamma_T_M_1.pdf